(51) International Patent Classification 5 :	A2	(11) International Publication Number:	WO 92/08456
A61K 31/415, 31/495, 31/195 C12Q 1/50		(43) International Publication Date:	29 May 1992 (29.05.92)

(54) Title: METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED

(57) Abstract

A method of inhibiting growth, transformation, and/or metastasis of mammalian cells, particularly epithelial cells, in which activity of at least one enzyme, which participates in purine metabolism or regulation of nucleotide levels or the relative ratios of their phosphorylated states, is elevated. In particular, a method of inhibiting transformation, growth and/or metastasis of mammalian cells in which a DNA tumor virus, a DNA tumor virus factor or other factor which has an equivalent effect on cells has acted.

METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED

Description

Background

Transformation, or malignant transformation, of cells results in changes in their growth characteristics and can cause them to form tumors in animals into whom they are introduced. For example, transformation of adherent cells can be associated with alterations such as changes in growth control, cell morphology, membrane characteristics, protein secretion and gene expression. Although transformation can occur spontaneously, it can be caused by a chemical or irradiation or may result from infection by a tumor virus. Little is known about the underlying molecular events. One type of RNA viruses (the retroviruses) and many different types of DNA viruses can act to transform cells and collectively are referred to as tumor viruses. In the case of tumor viruses, it is clear that the virus does not itself carry all of the genes necessary to produce the phenotypic changes characteristic of infected cells. Tumor viruses may act through a gene or genes in their genome (oncogenes) which, in some way, influence or induce target cell genes. The induced target cell genes, in turn, act to carry out the changes observed in transformed cells. There are at least three major

classes of transforming DNA viruses: adenoviruses, which have two groups of oncogenes, E1A and E1B, which act together to produce transformation; papovaviruses, which synthesize proteins, called T antigens, which may work together to transform cells; and herpes viruses, for which no oncogene has been identified as yet.

Although considerable effort has been expended in identifying transforming genes or oncogenes and, in some cases, has also resulted in identification of their protein products, very little is known about the cellular mechanisms affected in the transformation process. There is a consensus that these oncogenes perturb cell growth by modifying the expression or activity of key growth related genes. It would be very helpful to have a better understanding of how transformation occurs, particularly if the biochemical pathways affected can be identified. Such knowledge would make it possible to design compounds which can interfere with or counter the effects of the transforming signals and, thus, are useful in preventing transformation or minimizing the extent to which it occurs, once begun, and, thus, to reduce effects on individuals in whom it occurs.

Disclosure of the Invention

The present invention relates to a method of inhibiting growth, transformation and/or metastasis of mammalian cells in which activity of at least one purine metabolic enzyme is elevated (i.e., is

SUBSTITUTE SHEET

greater than that in the corresponding untransformed or normal cell). As used herein, the term purine metabolic enzyme includes any enzyme which participates in purine metabolism or in regulation of nucleotide levels or the relative ratios of the phosphorylated states (e.g., ATP/ADP), or both. In particular, the present invention relates to a method of inhibiting (preventing, reducing or reversing) transformation of mammalian cells by a DNA tumor virus, a DNA tumor virus factor (or product) or other factor (e.g., a cellular factor) which has an equivalent effect on cells as that of the DNA tumor virus or DNA tumor virus factor (i.e., causes, either directly or indirectly, an increase in purine metabolic enzyme activity). The present invention also relates to a method of inhibiting growth and/or metastasis of mammalian cells in which such a virus, virus factor or other factor has acted. The method is carried out by inhibiting (or interfering with) the increase in purine metabolic enzyme activity caused by the DNA tumor virus or factor, by contacting cells in which the level is increased with a drug capable of causing the desired effect (i.e., inhibition of purine metabolic enzyme activity). This is carried out, for example, by interfering with the ability of the virus or the factor to increase expression of a gene(s) which encodes a host cell purine metabolic enzyme(s) or by counteracting the increase in purine metabolic enzyme activity, directly or indirectly. In carrying out the present method, cells in which the

purine metabolic enzyme level is elevated are
contacted with the drug (or drugs) under appropriate
conditions: that is, conditions appropriate for the
drug to pass into the cell (in those embodiments in
which an intracellular effect is necessary) or under
conditions appropriate for the drug to remain at or
within cell membranes (in those embodiments in which
an effect at or within the cell membrane is
necessary). The present invention further relates
to compounds or drugs useful in reducing the effects
on cells of a DNA tumor virus, DNA tumor virus
oncogenic product, or other factor.

Drugs useful in the present method can have the
desired effect on cell transformation, growth or
metastasis by acting to combat an effect of the
viral product or other factor or to interfere with
action of the viral product in one or more of the
following ways: by inhibiting the purine metabolic
enzyme whose activity in the cell is elevated; by
decreasing the message level; by interfering with
the transcription factors which induce expression of
the host cell purine metabolic enzyme(s); by
inhibiting the interaction of the viral product or
other factor with a host cell gene(s) encoding a
purine metabolic enzyme(s); and by inhibiting
interaction of the viral product or factor with a
host cell gene product(s) that regulates or that is
recruited to regulate the activity or expression of
the purine metabolic enzyme(s).

Drugs useful in the present method can be
existing drugs, analogues of existing drugs or drugs

designed specifically for the purpose of reducing
purine metabolic enzyme activity, such as by
inhibiting the DNA tumor virus or its activity. The
present method is particularly useful in blocking
the ability of a papillomavirus oncogenic product
(e.g., an E7 product) to increase the expression of
the host cell creatine kinase gene, or
other host cell gene(s) which participates in purine
metabolism (e.g., in cervical epithelial cells).
Thus, it is useful in inhibiting transformation of
such cells.

Other tumors which are characterized by
elevated activity of a purine metabolic enzyme(s)
(i.e., greater activity than in the corresponding
untransformed or normal cell) and which are
associated, directly or indirectly, with the
presence of the DNA tumor virus, tumor virus factor
or other factor can be treated in a similar fashion.
For example, tumors that result from cellular
mutations that mimic the effects of infection by a
DNA tumor virus can be treated in a similar manner.
For instance, loss of anti-oncogene products Rb, DCC
or p53 may mimic infection by a DNA tumor virus,
leading ultimately to elevated activity of a purine
metabolic enzyme(s). These tumors are likely
candidates for treatment by the present method.

Through use of the present method, it is
possible to prevent, reduce or reverse
transformation of mammalian cells by DNA tumor
viruses, DNA tumor virus factors or other factors
that have an equivalent effect on cells and to

SUBSTITUTE SHEET

prevent, reduce or reverse growth and/or metastasis of transformed cells in which such a virus, virus factor, or other factor has acted. Thus, through use of the present method, it is possible to prevent tumor formation, reduce the extent to which tumor formation occurs, or to reverse the progress (e.g., growth or metastasis) of a primary or metastatic tumor.

Brief Description of the Drawings

Figure 1 shows colocalization of the E7 and E1a target sequences in the E2 promoter attached to the CAT gene.

Figure 2 shows the structural similarity between adenovirus E1a and papillomavirus HPV-16 E7 transforming proteins.

Figure 3 shows the sequence relationship between the adenovirus E2E promoter and that of the B isozyme of creatine kinase, with lines connecting identical nucleotides.

Figure 4 shows that the 12S product of E1a (which encodes the transforming protein) lacking the transactivation function activates expression of creatine kinase B (CKB).

Figure 5 shows that point mutations in domain 2 of E1a which disrupt transformation are also impaired for E1a-induced expression of CKB.

Figure 6 shows that amino-terminal deletions of E1a which disrupt transformation also result in an inability to induce expression of CKB.

Figure 7 shows part of the sequence of CKB gene, from which antisense oligonucleotides useful to block CKB translation can be determined.

Figure 8 is a graph illustrating the dose-related response of the DU 145 prostate carcinoma cell line to varying concentrations and durations of treatment with a homocyclocreatine preparation. The effects of 1.0 mM, 2.0 mM, 5.0 mM and 10.0 mM homocyclocreatine preparation on total incorporation of ^{3}H-thymidine are plotted as a percent of the untreated control for days 1 through 5, versus the concentration of homocyclocreatine preparation.

Figure 9 is a bar graph illustrating the inhibition of growth and the dose-related response of five colon carcinoma cell lines (SW1116, SW48, SW620, CACO2, and WIDR) to varying concentrations of cyclocreatine (0 mM, 3.5 mM, 7.0 mM, 14.0 mM, 28.0 mM, 42.0 mM, 56.0 mM and 70.0 mM) after 7 days of treatment. The height of each bar represents the counts per minute (cpm) of ^{3}H-thymidine incorporated at each drug particular concentration.

Figure 10 is a series of bar graphs illustrating the effect of 4 mg/ml drug on growth (as assayed by incorporation of ^{3}H-thymidine) of various cell lines as a percent of the untreated control. The cell lines include kidney (Vero, 293), embryonal (BALB/c3T3 (BALB)) lung (MRC-5, NCI-H69 (H69)), cervical (C-33A, HeLa, SiHa, CaSki, and ME-180), prostate (LNCaP.FGC (LNCAP), DU 145, and PC-3) and colon (SW1116, SW403, and SW48) cell

SUBSTITUTE SHEET

-8-

lines. Figure 10A shows the effect of a
homocyclocreatine preparation on growth of the cell
lines; Figure 10B, shows the effect of a
1-carboxymethyl-2-iminohexahydropyrimidine
preparation on growth of the cell lines; Figure 10C,
shows the effect of cyclocreatine on growth of the
cell lines; Figure 10D, shows the effect of
guanidinoacetate on growth of the cell lines.

Figure 11 is a bar graph illustrating one of
the observed trends of the antiproliferative
activity of homocyclocreatine and 1-carboxymethyl-
2-iminohexahydropyrimidine on the one hand, in
comparison to that of cyclocreatine. In this
drawing the height of the bar represents the
incorporation of ^{3}H-thymidine as a percent of the
untreated control for cervical carcinoma cell lines
C-33A, HeLa, SiHa, CaSki and ME-180 on treatment
with 4 mg/ml homocyclocreatine (HcCr), 1-carboxy-
methyl-2-iminohexahydropyrimidine (6CCr) or
cyclocreatine (CCr).

Figure 12 is a graph illustrating the anti-
proliferative activity of cyclocreatine in a human
tumor xenograft model. The average volume (mm^{3}) of
SW48-derived colon carcinoma tumors implanted in
nude mice fed 0.0 %, 0.5%, or 1.0% dietary
cyclocreatine is plotted against time (days
post-implantation).

Figure 13 is a graph illustrating the
anti-proliferative activity of cyclocreatine in a
second human tumor xenograft model. The average
change in volume (mm^{3}) of ME-180-derived cervical

SUBSTITUTE SHEET

carcinoma tumors implanted subcutaneously in nude
mice fed 0.0 %, 0.5%, 0.75% or 1.0 % dietary
cyclocreatine is plotted against time (days
post-implantation). Drug regimens were not
initiated until 24 days after tumor cell
implantation.

Detailed Description of the Invention

        Oncogenic products of DNA tumor viruses,
particularly those DNA tumor viruses associated with
transformation or tumors of epithelial cells, have
been shown to have certain functional, structural
and sequence similarities which make it reasonable
to expect that they have a common or similar effect
on host cells which results in induction of cellular
transformation. In addition, activity of an enzyme
which participates in purine metabolism or in
regulation of nucleotide levels or the relative
ratios of the phosphorylated states (i.e., a purine
metabolic enzyme) is known to be elevated
(increased) in transformed mammalian cells. In
particular, it is known that the activity of brain
creatine kinase (CKB or CKBB), which is a purine
metabolic enzyme, is characteristically elevated in
transformed cells and tumors in which a DNA tumor
virus or DNA tumor virus factor is present or on
which such a virus or virus factor has acted,
resulting in transformation or tumor formation. CKB
is characteristically elevated in many types of
tumors and is a reliable marker for at least one
tumor type (small cell lung carcinoma). CKB is

SUBSTITUTE SHEET

induced by at least one DNA tumor virus (i.e., adenovirus) and CKB induction correlates with the ability of the oncogenic region of the virus to transform cells.

In particular, it is known that the oncogenic products of two DNA tumor viruses, the E7 protein of human papillomavirus (HPV) 16 and the adenovirus E1a protein, have many similar functions in cells and are able to increase host gene expression. As described in detail herein, these similarities and the ability shown by these DNA viruses to induce cellular transformation appear to be linked to their ability to increase host cell gene expression, particularly their ability to increase expression of purine metabolic enzymes.

The present invention relates to a method of inhibiting growth, transformation, and/or metastasis of mammalian cells in which activity of one or more purine metabolic enzymes is elevated. This is carried out by inhibiting (reducing or eliminating) the ability of: (1) a DNA tumor virus, (2) a factor produced by or characteristically associated with a DNA tumor virus (a DNA tumor virus factor) or (3) other factor (e.g., a cellular factor) which has an effect corresponding to that of the DNA tumor virus or virus factor (a DNA tumor virus factor equivalent), to induce cellular transformation or to maintain a transformed phenotype and to cause an elevation of purine metabolic enzyme activity. The method is effected by interfering with the ability

SUBSTITUTE SHEET

of the virus or factor to increase expression of
such purine metabolic enzymes or by countering the
increase in purine metabolic enzyme activity.
Compounds or drugs useful in the present method are
also the subject of the present invention.

In particular, through use of the present
method, it is possible to inhibit the ability of a
DNA tumor virus, a DNA tumor virus factor, or other
factor which has an equivalent effect on cells, to
increase the expression of host cell enzymes, such
as creatine kinase, adenylate kinase, adenylate
cyclase and adenosine kinase, which participate in
purine metabolism or which interact with these host
cell enzymes. It is also possible by the use of
inhibitors of these enzymes to counterbalance the
induction effect caused by the virus. Thus, it is
possible to inhibit the ability of the DNA tumor
virus, DNA tumor virus factor, or other factor to
induce cellular transformation or to maintain the
transformed state. As a result, cellular
transformation, maintenance of transformation,
growth and/or metastasis is inhibited (i.e., it is
prevented or occurs to a lesser extent than would be
the case if the present method were not carried out
or is reversed, wholly or in part, once a cell has
been transformed).

The present method of inhibiting transformation
of mammalian cells in which purine metabolic enzyme
activity is elevated (i.e., greater than purine

metabolic enzyme activity in untransformed cells)
can have its effect by several different mechanisms.
For example, the ability of a DNA tumor virus, DNA
tumor virus factor or other factor to induce
transformation can be interfered with by:

1) inhibiting the purine metabolic enzyme(s)
whose activity in transformed cells is elevated as a
result of the effect of the virus or factor. This
can be carried out, for example, by administering a
compound or drug which reduces the activity of the
purine metabolic enzyme(s) or reduces the
association of two or more purine metabolic enzymes;

2) decreasing the message level/preventing
translation of the mRNA. This can be carried out by
administering antisense constructs which are
oligonucleotides selected to bind to a region of the
cellular purine metabolic enzyme mRNA necessary for
translation. For CKB, for example, one such region
has been defined and is that region at the 3' end,
shown in Figure 7;

3) interfering with transcription factors.
This can be carried out by modifying the activity or
association of unique factors with their specific
promoters. For example, drugs can be designed to
interfere with (prevent or modify) the association
of transcription factors with genes encoding purine
metabolic enzymes, in order to control the extent of
initiation and the amount of enzyme produced;

4) by inhibiting interaction of viral products
with host cell genes encoding the purine metabolic
enzymes. This can be carried out by identifying the

SUBSTITUTE SHEET

target and preventing the association with and/or activation of the promoter. The unique TTAA element on the CKB promoter, which is shared with the adenovirus E2E promoter, might be an excellent candidate; and

5) by inhibiting interaction of viral product(s) with host cell product(s), that regulate or are recruited to regulate the activity or expression of purine metabolic enzymes. This can be carried out by means of compounds designed to bind to the viral products and to inhibit binding of the host cell product with the viral product.

Because it is known that the activity of purine metabolic enzymes, such as creatine kinase, is elevated in mammalian cells transformed by a DNA tumor virus or virus factor, and because there are enzymes which work in conjunction with creatine kinase, such as adenosine kinase, adenylate kinase and adenylate cyclase, such enzymes might be useful as markers for identifying transformed cells. For example, the occurrence (presence/absence) or quantity of one or more of these enzymes can be determined, using known enzyme assays or specific probes from the isolated genes. The occurrence or quantity of one or more of the enzymes can be an indicator or marker useful for detecting transformation or viral infection of cells. The information can be used for diagnostic purposes or for monitoring treatment in an individual in whom diagnosis has been made.

The present method of inhibiting cellular transformation, growth and/or metastasis can be carried out using existing drugs, analogues of such drugs, or drugs specifically designed for the purpose. Drugs can be administered to produce inhibition of cellular transformation by direct interaction with the virus (e.g., by inhibiting production of viral DNA or mRNA expression of the encoded protein); by blocking the domain or sequence of the virus which is responsible for inducing expression of a cellular gene involved in cell growth perturbing functions; by blocking the activity of a factor, produced by or characteristic of the DNA tumor virus, which is the inducer of such a cellular gene; or by acting directly upon host cell products which interact with a viral product to cause transformation. Drugs may act at the enzyme level as well, so that the activity of the purine metabolic enzyme(s), which is elevated in the cell is reduced. Drug analogues and drugs designed for the specific purpose intended are also the subject of the present invention.

The following is a description of DNA tumor viruses able to induce cellular transformation, which can be inhibited by the present method; the basis upon which this inhibition is effected; the use of the present method in inhibiting cellular growth and/or transformation and compositions useful in the present method. It is important to note that in each of the instances described, in which cellular transformation occurs, the activity of host

SUBSTITUTE SHEET

cell creatine kinase is increased (is greater than the activity which occurs in the absence of transformation). Therefore, it is reasonable to expect that the present method can be used in the treatment of other tumors in which the activity of creatine kinase is increased significantly above activity in normal cells. Similarly, it is reasonable to expect that the present method can be used in inhibiting transformation of cells in which activity of other purine metabolic enzymes, particularly those which associate functionally with CKB, is increased. It is also possible to inhibit growth and/or metastasis of transformed cells (reduce the extent to which it occurs or prevent its occurrence) using the method and drugs described.

DNA Tumor Viruses

A)   Human Papillomaviruses and Association with
      Human Anogenital Cancers

As discussed by Phelps et al., recent studies have established a strong association between certain human papillomaviruses (HPVs) and some types of human anogenital cancers (Phelps, W.C. et al., Current Topics in Microbiological and Immunology, 144:153-166, Springer-Verlag, Berlin Heidelberg, (1989)). More than a dozen different HPV types have been isolated from epithelial tumors of the genital region. Precancerous lesions, such as moderate to severe cervical dysplasia and carcinoma in situ, as well as invasive cervical carcinoma, have been

SUBSTITUTE SHEET

associated with HPV types 16, 18, 31 and 33 (Zur Hausen, H. and A. Schneider, 1987, In: Howley, P.M., Salzman, N., Eds. The Papovaviridae: The Papillomaviruses, Plenum, NY, pp. 24-263). Of the HPVs which have been associated with anogenital malignancies, HPV-16 has been detected most frequently (greater than 60%) in biopsies from cervical carcinoma. RNA analyses for cervical carcinoma tissues and derived cell lines have revealed that the E6 and E7 ORFs are generally expressed, suggesting that their gene products may be necessary for the maintenance of the malignant phenotype. (Schneider-Gadicke, A. and E. Schwarz, EMBO J., 5: 2285-2292 (1986); Smotkin, D. and F.O. Wettstein Proc. Natl. Acad. Sci. USA, 83:4680-4684 (1986); Baker, C.C. et al., J. Virol, 61:962-971 (1987); Takebe, N. et al., Biochem. Biophys. Res. Commun., 143:837-844 (1987)). Morphological trans-formation of established rodent cells has been described for HPV-16 (Yasumoto, B. et al., J. Virol, 57:572-577 (1986); Tsunokawa, Y. et al., Proc. Natl. Acad. Sci. USA, 83:220-2203 (1986); Kanda, T. et al., Jpn. J. Cancer Res., 78:103-108 (1987)). This transforming activity has been localized to the E6/E7 region (Bedell, M.A. et al., J. Virol., 61:3635-3640 (1987); Kanda, T. et al., ibid, 62:610-613 (1987)). In addition, the HPV-16 E6/E7 region has been shown to encode a function capable of cooperating with an activated ras oncogene in the transformation of rat embryo fibroblasts

(Matlashewski, G. et al., EMBO J., 6:1741-1746
(1987)).

The immortalization function of HPV 16 has been
mapped to the E7 ORF by Phelps and co-workers.
(Phelps, W.C. et al., Current Topics in
Microbiological and Immunology, 144:153-166,
Springer-Verlag, Berlin Heidelberg, (1989)). These
researchers also found the E7 product of HPV-16 to
have activities similar to those of the oncogenic
product of another virus, the E1a protein of
adenovirus.

B)   Adenoviruses

Adenoviruses are a class of viruses which cause
upper respiratory infections in many animals. They
have been isolated from a wide range of species, and
at least 31 different serotypes of human
adenoviruses have been characterized (Luria et al.,
General Virology, pp. 360, 3rd Ed., Wiley & Sons,
New York (1978)). The basic molecular biology of
these viruses is very similar. The early adenovirus
gene products are oncogenes that have been shown to
be able to immortalize primary cells in culture. In
collaboration with a second oncogene, such as the
H-ras gene, they can transform cells in vitro.

The proteins encoded by the E1a region of the
adenovirus genome are necessary for efficient viral
replication and for viral transformation of cells in
culture. The E1a proteins contain three distinct
domains that are strongly conserved among adenovirus
subgroups and species (van Ormond, H. et al., Gene

SUBSTITUTE SHEET

12:63 (1980); Kimelman, D. _et al._, _J. Virol._ _53_:99 (1985)). The vast majority of domain 3 is unique to the 289 amino acid protein and is important for trans-activation of early viral promoters (Berk, A.J., _Ann. Rev. Genet._ _20_:45 (1986)). Domains 1 and 2 are required for transcriptional repression, transformation, and induction of DNA synthesis, but not for activation of transcription (Lillie, J.W. _et al._, _Cell_ 46:1043 (1986); Lillie, J.W. _et al._, _Cell_, _50_:1091 (1987)).

C) **Similarities Between Human Papillomavirus E7 Oncogenic Product and Adenovirus E1a Oncogenic Product**

In summary, the papillomavirus oncogenic product and the adenovirus oncogenic product described above have been shown to have the following similarities:

1)   Phelps _et al._ have shown that E7 has transcriptional transactivation properties analogous to those of adenovirus E1a. That is, E7 can affect heterologous promoters, including the adenovirus E2 promoter (Phelps, W.C. _et al._, In: _Current Topics in Microbiology and Immunology: Transforming Proteins of DNA Tumor Viruses_, Knippers, R. and Levine, A.J., Eds., Springer-Verlag, Berlin, Heidelberg, pp. 153-166 (1989)). The adenovirus E2 promoter sequences required for E1a stimulation and

SUBSTITUTE SHEET

HPV-16 E7 activation have been shown to be coincident.

Figure 1 is taken from Phelps et al. (Phelps, W.C. et al., In: Current Topics in Microbiology and Immunology: Transforming Proteins of DNA Tumor Viruses, Knippers, R. and Levine, A.J., Eds., Springer-Verlag, pp. 153-166 (1989)). The figure is a schematic representation of the E7 target sequence in the adenovirus E2 promoter linked to the CAT gene. Bal31 deletions with end points at -97, -79, -70 and -59 derived from the -285 to +40 AdE2CAT plasmid were generated. Five micrograms of each Ad E2CAT plasmid together with 5 µg of either PBR322, PE1A (a plasmid encoding adenovirus E1a product) or p858 (a construct expressing the papillomavirus E7 product) were cotransfected into CV1 monkey cells and assayed for CAT activity. The locations of the E2F binding sites and its major and minor RNA initiation sites are shown.

2) Comparison of the amino acid sequences of HPV-16 E7 and adenovirus E1a proteins reveals regions of significant amino acid similarity which are well conserved within the E7 proteins of other papillomaviruses present in genital tissues.

Figure 2, taken from Phelps et al., (ibid), shows structural similarity between Adenovirus E1a and HPV-16 E7. A schematic diagram of the Ad5 E1a region is shown at the

SUBSTITUTE SHEET

top of the figure with the conserved amino acid domains 1-3 indicated. Homologous (boxed) and functional (hatched) amino acids of domains 1 and 2 from E1a which are found in HPV-16 E7 are located within the N-terminal 37 residues. The predicted amino acid sequences for this region of the E7 proteins of the other genital-associated HPVs are shown.

3)   The conserved sequences between E1a and E7 mentioned above are restricted to domains 1 and 2 of E1a. Those sequences are important for the ability of E1a to transform and induce DNA synthesis. (Lillie, J.W. et al., Cell 46: 1043-1051 (1986)).

4)   Both E1a and E7 associate with the anti-oncogene product of the retinoblastoma (Rb) gene (Dyson, N. et al., Science 243: 934-937 (1989)). The conserved sequences between the two proteins which are important for transformation are also important for the association with the Rb protein. This suggests that the two proteins interact with the same cellular metabolic events to cause transformation.

5)   E7 can complement the ras oncogene in transforming baby rat kidney cells in a similar fashion to E1a complementation of the ras oncogene (Phelps et al., ibid).

Thus, two DNA tumor viruses, each belonging to a different class of DNA viruses, have been shown to have structural and sequence similarities and to

modulate host gene expression. Both E7 and E1a
appear to possess multiple functions and it is
reasonable to assume that their ability to modulate
host gene expression is an important event in their
ability to induce cellular transformation. If the
cellular gene products which are targets for such
oncogenic regulators which require the transforming
domains of these DNA tumor viruses were identified,
it would not only provide great insight into
metabolic events which are affected during
transformations, but also provide a means by which
transformation by such DNA tumor viruses can be
inhibited. In addition, it would make it possible
to design markers useful in diagnosing infection
with the responsible DNA virus and in monitoring
subsequent transformation. It would also make it
possible to design compounds or drugs useful for
inhibiting activated targets or activation events,
which could serve as chemotherapeutic drugs.

    As described in the following sections, it has
been determined that at least one cellular enzyme
which is involved in energy metabolism and purine
pathways (i.e., creatine kinase) and which is a
tumor marker is a reasonable target of DNA tumor
viruses. The oncogene proteins of the DNA tumor
viruses act on host/cellular genes and modify
expression of some selected genes, resulting in
induction of a transformed state.

Identification of Cellular Gene Products Which are Targets for Oncogenic Regulators

It is reasonable to expect that a cellular gene product, creatine kinase, which is an enzyme involved in maintenance of ATP at sites of cellular work or energy production, is a target of oncogenic products of DNA tumor viruses, such as the HPV E7 product and the adenovirus E1a product, which act as regulators and modify or regulate expression of cellular genes. In addition to discrete DNA tumor viruses, there appear to be factors which are consistently present in or secreted from some transformed cells or tumor cells, which in and of themselves are capable of inducing DNA synthesis in host cells and probably are able to modulate cellular gene expression with much the same effect that a DNA tumor virus has (i.e., increase in expression of the cellular gene). Such factors are referred to herein as DNA tumor virus factors.

Creatine kinase has been shown to be a target for phosphorylation by protein kinase C and tumor promoters. It is highly responsive to a variety of hormonal signals and has been associated with signal transduction mechanisms. Creatine kinase is elevated in a variety of tumors and has been described as a tumor-associated marker. For example, creatine kinase is used as a diagnostic marker for small cell lung carcinoma (Gazdar, A.F. et al., Cancer Res., 41:2773-2777 (1981)). High levels of creatine kinase are found in breast and prostate carcinomas, especially in the presence of

SUBSTITUTE SHEET

overt metastasis (Silverman, L.M. et al., Clin.
Chem., 25:1432-1435 (1979); Homberger, et al., Clin.
Chem. 26: 1821-1824 (1980); Thompson et al., Lancet
98: 673-675 (1980)). In breast cancer, the tumor
burden correlates well with the degree of elevation
of brain creatine kinase. In cancers of the
bladder, prostate, testis, head and neck, raised
serum creatine kinase B levels occurred more
frequently in patients with metastatic disease than
in those thought to have local disease alone, while
in sarcoma, cancer of the ovary, uterus, cervix,
stomach, bowel and anal canal, the presence of
persistent disease correlated with high serum CKB
levels (Rubery, E.D. et al., Eur. J. Cancer Clin.
Oncol., 18:951-956 (1982)). In neuroblastomas, the
extent of the disease was associated with an
increased incidence of elevated serum creatine kinse
B. The highest pre-treatment blood levels were found
in stage IV disease, and a strong correlation
between the pretreatment CKB level and the outcome
of the disease in patients with neuroblastomas was
observed (Ishiguro, Y. et al., Cancer 65: 2014-2019
(1990)).

It is clear that CKB is an enzyme that is very
active in many tumors, particularly those of epi-
thelial origin (e.g., small cell carcinoma,
neuroblastomas retinoblastomas, cervical carcinomas,
bladder cancer, and ovarian cancer). Some of these
malignancies may be triggered by a DNA tumor virus
or DNA tumor virus factor. Alternatively,
transformation could result from the action of other

factors (e.g., cellular factor, growth factor), which have an effect on cells equivalent to that of DNA tumor virus or virus factor. For example, activated oncogenes, mutated tumor suppressors or anti-oncogenes, or autocrine growth factors may also act to increase purine metabolic enzyme activity. The present method of inhibiting growth, transformation, and/or metastasis of mammalian cells, is applicable to cells transformed by diverse mechanisms in which the activity of at least one purine metabolic enzyme is elevated.

As discussed below, creatine kinase has several characteristics which support the idea that it is such a target of oncogenic products of DNA tumor viruses. As is also discussed below, other enzymes which have a similar role in cellular metabolism (i.e., purine metabolic enzymes) and which work in association with CKB are likely to be targets of oncogenic products as well. Thus, interference with the ability of an oncogenic product of a DNA tumor virus, DNA tumor virus factor, or other factor which has an equivalent effect on cells to regulate expression of enzymes which participate in purine metabolism and/or interference with another enzyme(s) which interacts with the purine metabolic pathway enzyme(s) will result in inhibition of or interference with the ability of such viruses or factors to transform cells. This should be particularly useful in inhibiting tumor formation, growth or metastasis in epithelial cells and, particularly, in epithelial cells in which HPV is known to be

present (e.g., cervical epithelial cells). The
method of the present invention makes it possible to
inhibit the ability of DNA tumor viruses to act as
mediators of cell transformation, and thus, to
inhibit cell transformation or tumor formation or
spread, by acting upon production of viral DNA, RNA
or encoded oncogenic products, as well as by
interfering with other viral or cellular products
which normally interact or cooperate with viral or
cellular products to bring about cell
transformation.

The gene encoding human brain creatine kinase
(CKB) has been isolated and sequenced and its
promoter has been shown to have a strong sequence
relationship with the promoter region of the
adenovirus E2E gene (Figure 3; Daouk, G.H. et al.,
J. Biol. Chem. 263(5): 2442-2446 (1988)). The E2E
gene of adenovirus encodes a 72 Kd single stranded
DNA binding protein which is involved in virus
replication (Friefeld, B.R. et al., Virology,
124:380-389 (1983)). The expression of the E2E gene
is highly dependent on the adenovirus oncogenic
products of the E1a region (Berk, A.J., Ann. Rev.
Genet., 20:45-79 (1986)). The first 95 bases of the
E2E and CKB promoters are shown in Figure 3. Solid
lines connect identical bases. This is the first
example of a strong sequence similarity between a
cellular gene promoter region and a viral gene pro-
moter. It has also been shown that brain creatine
kinase expression is regulated by the oncogenic
products of the E1a region of the adenovirus. Thus,

SUBSTITUTE SHEET

it has been shown that a cellular gene which is associated with energy metabolism and regulation of intracellular nucleotide levels is turned on, or activated, by the transforming region of an oncogene encoded by a DNA tumor virus. Induction of a cellular gene by oncogenic products has thus, been shown for the first time to require both of the transforming domains of the oncogenic protein of the virus (Kaddurah-Daouk et al., Mol. Cell. Biol. 19(4): 1476-1483 (1990)).

The unexpected sequence relationship between the E2E promoter to the CKB promoter region promoters prompted an investigation of a possible functional relationship between the two. Infection in tissue culture of a variety of human cell lines (e.g., cervical cells, monocytic cells and small cell carcinoma) has demonstrated that CKB expression is activated by adenovirus infection in every cell line tested that previously had a detectable CKB level. The E1a proteins of the oncogenic region are important for the induction, as is shown by the fact that infection with a deletion virus mutant dl312, which does not include the E1a region, is defective for induction.

What was striking was that domains one and two of the E1a molecule, which are associated with transformation and induction of DNA synthesis in host cells, are the same domains required for induction of CKB activity, as illustrated in Figures 4, 5 and 6. Figure 4 shows that infecting HeLa cells with a mutant virus (dl 1500) that expresses

only the 12S product (associated with trans-
formation) results in induction of CKB expression to
an extent comparable to that seen when HeLa cells
are infected with the 13S product, which encodes the
entire protein with all three domains. Lanes a and
b, mock infected plates probed with CKB probes;
lanes c and d, RNA harvested from a dl 1500-infected
plates (12S product producer) and probed with CKB
probes; lanes e and f, results of probing RNA
harvested from cells infected with pm975 virus
(expressing 13S product).

Figure 5 shows that point mutations in
transforming domain 2 are impaired for E1a-induced
expression of CKB. HeLa cells were infected with
different mutant viruses. In Figure 5A, the lanes
are as follows: lane a, mock infection; lanes b, g,
wild-type pm975 virus (13S product); lane c mutant
dl 312 (an E1a deletion mutant); lanes d, e, h, i,
mutant viruses pm 975-936 and 953, each of which has
a point mutation in domain 2 and disrupts the
ability of E1a to transform; lanes f, j, mutant
virus pm 975-1098, which has a point mutation in
domain 3 and does not affect transformation
functions. Panel B shows results of probing the
same RNA with adenovirus E2 probes.

Figure 6 shows that amino terminal deletions of
E1a obliterate the induction of expression of CKB.
HeLa cells were infected with amino terminal deleted
viral constructs. Panel A shows creatine kinase
activity, represented by bars. Panel B shows amino
acids deleted in each mutant (right) and names given

by Whyte and co-workers (Whyte, P. _et al._, _J. Virol._ _62_: 257-265 (1988)). The same observation is seen when RNA harvested from cells is probed with CKB specific primers (data not shown).

Thus, the induction of CKB, which is a major enzyme in energy metabolism, regulation of nucleotide levels and purine pathways, associates well with the ability of E1a to transform. This leads to the conclusion that CKB induction must be part of the mechanism by which cells are transformed by at least one DNA tumor virus (adenovirus type 5).

In addition, as described above, the papilloma-viruses (e.g., type 16), which are associated with malignancies of the cervix, encode a protein (the E7-encoded protein) which is very similar in sequence and function to that of the E1a-encoded protein in the transforming region. In particular, several key similarities have been identified: (1) the E7-encoded protein has amino acid sequence homology to the E1a-encoded protein in the important transformation domain; (2) the E7-encoded protein, like the E1a-encoded protein can act to turn on the adenovirus E2 promoter; (3) both proteins interact with similar host proteins, such as the retino-blastoma gene product; and (4) the E7-encoded protein can replace the E1a-encoded protein in transformation assays in which complementation with ras is tested.

It is also important to note that the sequence of the adenovirus E2 promoter, which controls the replication of adenovirus, is very similar to that

SUBSTITUTE SHEET

of the cellular CKB promoter. Either E1a of
adenovirus or E7 of papillomavirus virus can induce
the E2 promoter and they both require the first 90
bases of the promoter for induction. E1A turns on
CKB expression and because the first 90 bp of the
CKB promoter sequence are very similar to those of
the E2 promoter, it is reasonable to expect that E7
acts similarly (i.e., turns on CKB expression). In
addition, the fact that the transforming domains 1
and 2 of E1a are required for CKB induction by the
adenovirus and the fact that the same sequences of
the two domains are conserved in the E7 protein of
papillomavirus strongly suggest that CKB will be
induced by E7 and would require the transformation
domains of E7. Mutations which disrupt the ability
of E1a to transform are dysfunctional for CKB
expression. These crucial amino acids are conserved
in the transforming part of E7. It is likely that
these two DNA tumor viruses cause some similar
modifications in the host cell metabolism and hence
work at least partially via common mechanisms to
cause transformation. It has been shown that CKB
associates with the ability of E1a to transform
cells. It is reasonable, based on experimental
proof and the literature, to predict that creatine
kinase or the metabolic pathway is similarly
affected in epithelial cells (e.g., epithelial cells
of the cervix) which are infected by papilloma-
viruses associated with malignancies. After infec-
tion of an epithelial cell by such a virus and
expression by the virus of the encoded transforming

SUBSTITUTE SHEET

proteins, increased expression of CKB and the
enzymes working in conjunction with it (e.g.,
adenylate kinase and cyclase) occurs. Detection of
some or all of these enzymes can serve as the basis
for determining whether the virus is present and, if
necessary, the extent to which it occurs.

Inhibition of Growth Factors Induced in Transformed or Virally Infected Epithelial Cells

For non-transformed mammalian cells to grow in
vitro, they require the presence of appropriate
polypeptide growth factor(s) that exert their
effects through specific plasma membrane receptors.
Primary epithelial cells are hard to grow in
culture. This has hindered the study of epithelial
cell transformation in vitro, and explains why most
in vitro transformation experiments have been done
with fibroblasts, although malignant tumors of
non-epithelial cell origin account for only 10-20%
of human neoplasms. However, human and rodent
primary epithelial cells can be transformed with
adenovirus, a DNA tumor virus (Houweling, A.P. et
al., Virology 105:537-550 (1980); Vander Elsen, P.J.
et al., Virology 131:242-246 (1983); Whittaker, J.L.
et al., Mol. Cell. Biol. 4:110-116 (1984)).
Adenoviruses normally infect quiescent
epithelial cells and the expression of the
adenovirus type 5, Ela 12S gene product enables
primary rodent epithelial cells to proliferate in
the presence or absence of serum (Quinlan, M.P. and
T. Grodzicker, J. Virol. 61:673-682 (1987)). Thus,

SUBSTITUTE SHEET

the 12S gene product provides a means of studying
the changes involved in the immortalization and
transformation of primary epithelial cells. The 12S
gene is a member of the adenovirus Ela transcription
unit. At early times, after infection, and in
transformed cells, two Ela transcripts designated
13S', 12S' mRNAs are produced. These mRNAs are
translated into proteins of 289 and 243 amino acids,
respectively, that differ only by the presence of an
additional internal 46 amino acids in the 289 amino
acid protein.

The products of the Ela region can immortalize
primary cells (Moran, E. et al., J. Virol. 57:
765-775 (1986)) and can cooperate with other viral
genes and cellular oncogenes to transform primary
rat cells (Ruley, H.E., Nature 304:602-606 (1983)).
The Ela 12S protein seems to play a major role in
the stimulation of cell proliferation responses.
The 12S gene product is required for optimal virus
production in growth arrested permissive cells, but
not in actively growing cells (Spindler, K.R. et
al., J. Virol. 53:742-750 (1985)). It induces
cellular DNA synthesis and cell cycle progression in
quiescent cells (Quinlan, M.P. and T. Grodzicker, J.
Virol. 61:673-682 (1987); Spindler, K.R. et al.,
ibid); Stabel, S.P. et al., EMBO J. 4:2329-2336
(1985)). It can immortalize primary epithelial
cells so that they retain many of their differential
characteristics.

The 12S product has been shown to cause/trigger
the production of a growth factor, when introduced

into primary kidney quiescent cells. Such a DNA tumor virus factor is a substance produced by or associated with a DNA tumor virus in a transformed or tumor cell and is capable of inducing immortalization in the absence of the DNA tumor virus itself. For example, recently Quinlan *et al.* (Quinlan, M.P. *et al.*, PNAS 84:3283-3287 (1987)), found that infection of primary baby rat kidney cells with an adenovirus variant that encodes only the 12S product results in production of a growth factor that stimulates primary epithelial cells to proliferate. Media from cells that were infected with this variant virus, was filtered (to remove intact virus) and fed to cells which never saw the virus. Results showed that this conditioned media was able to induce epithelial cell DNA synthesis and proliferation between 24 and 36 hours after addition. A growth factor seems to be secreted from the epithelial cells upon infection with the 12S virus. The factor can act in an autocrine fashion and has a large molecular weight. The growth factor appears to be a unique mitogen for epithelial cells. Although it has been shown that the 12S product of adenovirus can induce DNA synthesis, proliferation, immortalization or transformation of its host cell, it is unclear how induction occurs. Other DNA tumor viruses associated with malignancies show sequence similarity to the 12S protein of adenovirus and most probably secrete similar factors.

It appears that the growth factor released by 12S adenovirus infection might be mediating the

SUBSTITUTE SHEET

observed effects of the 12S product
(immortalization, induction of DNA synthesis). As
described previously, the 12S product is capable of
inducing the expression of CKB. The regions
required to induce CKB expression or the production
of the viral factor are similar. This suggests that
the virus might be affecting the host cell genes via
the secreted factor. Hence, the factor which is the
hormone might be the real inducer of CKB and other
enzymes. Adjacent epithelial cells contacted by
these factors may be stimulated to elevate purine
metabolic enzyme activity, while undergoing DNA
synthesis and proliferation. These cells may become
transformed ultimately, or may secrete factors,
enzymes or metabolites that are used by the original
transformed cell. This model is further favored by
the fact that the kinetics of induction of CKB and
the factor are similar. It is reasonable to expect
that this factor (or derivatives thereof) is
secreted by many tumors in which CKB (and adenosine
metabolic enzymes) is highly activated. Further
support for this idea is the fact that many DNA
tumor viruses, such as polyoma and papilloma virus
encode transforming products with amino acid
sequences similar to the amino acid sequence of the
adenovirus 12S products. Thus, cells infected with
such viruses are very likely going to express this
DNA tumor virus factor or transforming factor and
cause induction of purine metabolic pathway enzymes
in much the same manner as the 12S factor causes
induction.

SUBSTITUTE SHEET

The CKB gene is known to be very responsive to multihormonal signals, implying it is indeed active in signalling or is along a metabolic path that mediates these effects. Thus, this adenovirus factor might be a new hormone which also regulates CKB. Most of these hormones, in spite of being different and having different receptors, might pass by or affect a common event which CKB is part of.

A seemingly unrelated virus, the cytomegalovirus, which induces CKB expression (Colberg-Poley, A.M. et al., Virology, 166(1):217-228 (1988)), also appears to induce production of a factor capable of stimulating DNA synthesis and modifying cell growth (Gonczol, E. and S. A. Plotkin, J. Gen. Virol., 65:1833-1834 (1984)). This factor appears to function, at least partially, by modifying microtubule structure. Creatine kinase is thought to associate with the microtubule structure (Eckert, B.S. et al., J. Cell. Biol. 86: 1-5 (1980)). This factor might be the inducer of CKB expression.

Interruption of the autocrine loop which links this growth factor and its induction of enzymes, using selected drugs (e.g., competitive factor antagonists) can be carried out, using competitive antagonists which interfere with effects of the factor. Drugs may also interfere with the ability of the factor to act on cells, blocking autocrine stimulation or stimulation of adjacent cells. In addition, antibodies against the factor or receptor it interacts with can be used to block the factor's

SUBSTITUTE SHEET

effect. Such compounds can be used for the
treatment of virally infected cells and tumors of
epithelial origin.

Uses of the Present Method

Because of the increased levels of CKB and
other cooperative enzymes, simple enzyme assays can
be used to detect a DNA tumor virus in cells in
which one is thought to be present. Such assays can
also be used for diagnostic purposes or for
monitoring treatment provided to an individual in
which the presence of transformed cells has been
detected. Enzyme assays may also be used together
with other methods of diagnosis. For example, the
sensitivity of cytologic examination (Papanicolaou
smear test) carried out in conjunction with
detection of human papillomavirus (HPV) may be
superior to the use of either cytologic studies or
HPV detection alone in evaluating patients with
cervical lesions (Ritter, D.B. et al., Am. J. Obst.
Gynecol., 159(6): 1517-1525 (1988)). However,
presently-available methods for detection of HPV,
such as Southern blots which use labelled probes
from the virus, are often technically difficult,
time consuming, or costly. In contrast, enzyme
assays are practical, rapid (e.g., in this case,
approximately 25 minutes), inexpensive and easy to
carry out in clinical settings. The detection of
infection with HPV, through the method of the
present invention, can be substituted for Southern
blotting or other technically difficult, time

SUBSTITUTE SHEET

consuming or costly methods, as a routine assay to complement the Papanicolaou smear test.

For example, a diagnostic assay can be carried out as follows: proteins can be extracted from cervical scrapings, such as those obtained for cytologic evaluation and extracted (e.g., by freeze-thawing). The supernatant can be assayed for enzymes of interest (e.g., creatine kinase, adenylate kinase). Two or more enzymes can be assessed simultaneously. Such enzyme assays can measure, for example, CKB activity, as well as activity of one or two additional enzymes along the purine metabolic pathway.

A drug or compound suitable for use in the method of the present invention is one which: (1) is able to affect cells in which a DNA tumor virus, DNA tumor virus factor, or other factor which has an equivalent effect on cells has acted to cause, directly or indirectly, an elevation of the activity of a purine metabolic enzyme(s) and (2) is able to prevent the transforming domain of the oncogenic virus, tumor virus factor or other factor which has an equivalent effect on cells from inducing the purine metabolic activity or is able to inhibit the activity of the purine metabolic enzyme, directly or indirectly. The drugs can act outside of the cell, (e.g., by blocking the effect of a secreted factor or enzyme, by influencing uptake of creatine), or can enter the cell to act within the cell in one or more of the above-described ways. A drug having these characteristics can be a protein, peptide, a

SUBSTITUTE SHEET

nucleic acid sequence, or an agent which acts, directly or indirectly, to reduce the velocity of a purine metabolic enzyme. For example, inhibitors, substrate analogs, or slow substrates of a purine metabolic enzyme will, when present with the natural substrate(s), reduce the velocity of the enzymatic reaction catalyzed by a purine metabolic enzyme on the natural substrate(s). Note that preventing induction of a purine metabolic enzyme(s) in a cell in which its activity is elevated will also reduce the velocity of reaction. Drugs useful in the present method can be selected or designed to act in one or more of the above-described ways.

The drug(s) is administered to an individual in whom a DNA tumor virus or virus factor has acted, resulting in a cellular abnormality or a tumor. The drug is administered in sufficient quantity to reduce or eliminate the effect of the DNA tumor virus, virus factor, or other factor on cells.

For example, a drug which is an antisense construct (e.g., oligonucleotide sequence) which binds selectively to a region of the RNA necessary for translation can be used. In the case of CKB, the oligonucleotide sequence is one which binds selectively to a region of CKB RNA, as represented in Figure 7, which is needed for translation. The effects of the transforming viral DNA are, as a result, reduced or prevented. That is, an oligonucleotide sequence capable of entering the cell and binding (hybridizing) to the specific activated message to block it can be introduced into

SUBSTITUTE SHEET

cells. Hybridization to the nucleotide sequence renders it unavailable for further activity. In another approach, a drug which interferes with a transcription factor (e.g., by acting upon a promoter or blocking the ability of a transcription factor(s) to activate a promoter(s)) is administered in sufficient quantities to have the desired effect. Alternatively, a drug which inhibits interaction of the viral oncogenic product(s) (e.g., the E7 product, E1a product) with a cellular gene encoding a purine metabolic enzyme can be administered. Inactivation can occur, for example, by binding of the drug to the viral oncogenic product or by destruction of the viral oncogenic product by the drug.

Drugs which act to inhibit the activity of a purine metabolic enzyme(s) which is elevated in transformed cells may act directly or indirectly. Inhibition will result in a decrease in the activity of the purine metabolic enzyme(s), and of the velocity of the reaction in particular. For example, the drugs may act by interfering with the ability of purine metabolic enzymes to associate or interact with one another, or by altering the activity of an enzyme in the pathway resulting in decreased velocity of the purine metabolic enzyme whose activity is elevated.

The particular target is determined by the activity elevated in the cell. For example, the cellular gene encoding the purine metabolic enzyme adenosine deaminase has been shown to have a

striking resemblance (sequence similarity) at the
promoter level to brain creatine kinase.
Preliminary data shows that the adenosine deaminase
promoter, like the promoter of brain creatine
kinase, is induced by the E1a products. This is of
particular interest because adenosine deaminase is
also a tumor antigen/thymus leukemia antigen, is
involved in adenosine metabolism, and is vital for
DNA synthesis. By use of the present invention,
transformation, growth and/or metastasis of cells in
which the activity of adenosine deaminase is
elevated could be inhibited.

Adenylate kinase is another purine metabolic
enzyme which can be inhibited by the present method
and whose inhibition may result in inhibition of
cellular transformation. Adenylate kinases (NTP:
AMP phosphotransferases, N, adenine or guanine) are
relatively small (21-27 kD), monomeric enzymes which
catalyze the interconversion of nucleotides
according to the equation: Mg^{++} NTP + AMP $\rightleftharpoons$ Mg^{++}
NDP + ADP. The enzyme is ubiquitous, is abundant in
tissues where the turnover of energy from adenine
nucleotides is high (Noda, L., In: Enzymes, (Boyer,
P., ed.) Vol. 8, pp. 279-305, Academic Press,
Orlando, Fl), and has an important role in
maintaining energy charge of the adenylate pool
(Lipman, F., Curr. Top Cell. Regul., 18:301-311
(1981); Atkinson, D.E., Biochemistry, 7:4030-4034
(1968)). The prokaryotic gene from E. coli has been
cloned (Brune, M. et al., Nucleic Acids Res.,
13:7139-7151 (1985). This and previous studies

SUBSTITUTE SHEET

(Glaser, M. et al., J. Bacteriol., 123:128-136
(1975)) have shown that adenylate kinase is a key
enzyme in controlling the rate of cell growth. By
the method of the present invention, the activity of
adenylate kinase in tumor cells in which adenylate
kinase is elevated may be inhibited. Furthermore,
by virtue of its association with creatine kinase
and/or because it can provide dinucleotide
substrates for creatine kinase, inhibiting the
activity of adenylate kinase is expected to decrease
the velocity of creatine kinase.

The isozymes of creatine kinase catalyze the
resynthesis of ATP for use by cellular ATPases,
processes of contraction, macromolecular synthesis,
and maintenance of ion gradients, for example
(Bessman, S.P. and C.L. Carpenter, Ann. Rev.
Biochem., 54:831-62, (1985)). Creatine, creatine
phosphate and creatine kinase have been proposed to
facilitate energy distribution in several tissues,
such as muscle, heart and brain by means of the
creatine phosphate shuttle.

There are many possible sites for the action of
drugs that inhibit brain creatine kinase and/or
other enzymes which participate in purine
metabolism. Thus the effects of such drugs can be
direct or indirect, operating by mechanisms
including, but not limited to influencing the uptake
or biosynthesis of creatine, the function of the
creatine phosphate shuttle, inhibiting the enzyme
activity, or the activity of associated enzymes, or

SUBSTITUTE SHEET

altering the levels of substrates or products of a
reaction, to alter the velocity of the reaction.

In the method of the present invention, at
least one drug which is capable of inhibiting the
induction or activity of a purine metabolic enzyme
(e.g., adenylate kinase or creatine kinase) or
another enzyme which participates in the purine
metabolic pathway, or a cellular component which
cooperates with a purine metabolic pathway enzyme is
administered to an individual in a manner
appropriate for introducing the drug into affected
cells. A drug of the present invention may also be
administered in combination with other drugs known
to be effective in treatment or with one or more
additional drugs of the present invention. One or
more drugs affecting a single target or affecting
one or more targets in the pathway may be
administered to increase the effectiveness of
inhibition. The form in which the drug(s) will be
administered is determined by the type of drug used,
as will the route of administration and the quantity
given.

For example, in the case of an individual in
whom cervical dysplasia or cervical carcinoma is
present, a drug which is able to inhibit the
activity of the HPV oncogenic products and, thus,
inhibit modulation of the cellular gene (e.g., the
CK gene, adenylate kinase gene) is administered in a
therapeutically effective quantity. Such a drug can
be, for example, a peptide which binds domains 1
and/or 2 of E1a or E7, to prevent them from inducing

their transactivation activity. Alternatively or in addition, inhibitors of the activated cellular enzymes are administered. In this instance, as well as in other instances of epithelial tumors, the drug(s) can be administered topically or can be injected, infused or otherwise introduced, alone or in combination with other drugs of the present invention or other known therapies.

A further application of the work described herein is identification of existing compounds, analogues of such compounds or new drugs capable of inhibiting or counteracting the effects of DNA tumor viruses, tumor virus factors, or other factors with an equivalent effect on cells. For example, tumor cells which display an elevation of purine metabolic enzyme activity can be exposed in culture to a drug candidate, and then assayed for growth by the incorporation of tritiated thymidine into DNA. Drugs that cause a decrease in growth relative to the untreated control in such an assay or drug candidates which decrease the activity of purine metabolic enzymes in assays in vitro may be used to inhibit growth, transformation, or metastasis by the method of the present invention. A variety of presently-available drugs (described below) can also be assessed for their ability to inhibit creatine kinase or adenylate kinase, which seems to work in conjunction with creatine kinase and can serve as models for design of additional drugs for creatine kinase inhibition.

SUBSTITUTE SHEET

The sensitivity of tumor cell lines to inhibition of growth by cyclocreatine appears to correlate with creatine kinase activity. In particular, as shown herein, the more CK activity present in the cell, the more sensitive the cell is to the antiproliferative effects of cyclocreatine. This observation suggests that these and other tumor types having high creatine kinase activity or having creatine kinase activity which is elevated relative to that of the corresponding normal cell type, will be susceptible to inhibition by cyclocreatine (sensitive to cyclocreatine). Thus, the invention further relates to a method of identifying tumors which will be amenable to treatment with cyclocreatine (i.e., which are sensitive to cyclocreatine). In the method, the creatine kinase activity of a tumor specimen and/or a serum sample as appropriate is determined. Tumor samples having high creatine kinase activity, or having creatine kinase activity which is elevated relative to that of a corresponding normal cell type (i.e., a normal sample), are expected to be sensitive to cyclocreatine. Similarly, elevated serum creatine kinase levels (compared to a serum levels in a normal individual or normal baseline value) can be indicative of sensitivity to cyclocreatine of a tumor (e.g., primary, metastatic).

Drugs useful in the present method can be existing substances, analogues of existing substances or substances designed specifically to interfere with the action or effects of DNA tumor

viruses, DNA tumor virus factors, or other factors which have an equivalent effect on cells. The following is a description of existing substances known to inhibit creatine kinase, adenylate kinase or adenosine kinase. It will be possible to modify the substances described below to produce analogues which have enhanced characteristics, such as greater specificity for the enzyme or the oncogenic product, enhanced stability, enhanced uptake into cells, tighter binding to the enzyme or the oncogenic product or better inhibitory activity. In addition, based on knowledge of the structural and functional characteristics of the oncogenes and of the cellular genes upon which the oncogenic products act, it is possible to design other drugs useful in the present method.

Compositions Useful in the Present Method of Inhibiting Purine Metabolic Enzymes

Compounds which inhibit CKB and/or other enzymes which participate in purine metabolism, directly or indirectly (e.g., by interacting with enzymes in the pathway) to reduce the velocity of the enzyme will have great value in preventing and/or treating tumors characterized by elevated levels of these enzymes (e.g., cervical tumors). Such tumor cells may require elevated levels of CKB and/or other enzymes which participate in purine metabolism to meet their high energy demands for growth and metastasis. An advantage of drugs that target pathways that seem to be preferentially

SUBSTITUTE SHEET

required by tumor cells, is that they may be specifically toxic to tumor tissues, and thus may lack the general toxicity associated with less specific drugs.

These drugs can be inhibitors (e.g., irreversible inhibitors), substrate analogs, bi-substrate analogs, transition state analogs and/or slow substrates of a purine metabolic enzyme, which when present, reduce the velocity of the enzymatic reaction catalyzed by a purine metabolic enzyme on the natural substrate(s). For example, a transition state analog covalent inhibitor can be applied locally (e.g., in the cervix). In addition, inhibitors of the enzymes that work in conjunction with CKB can now be designed and used, individually, in combination or in addition to other drugs, to make control of the effect on CKB tighter. For example, inhibitors of adenylate kinase, an enzyme that physically and functionally associates with creatine kinase, can be designed. Such drugs, alone or in combination, are useful as antitumor agents.

The following are drugs which can be used, alone, in combination, or in combination with existing therapies in the method of the present invention in order to inhibit the purine metabolic enzyme indicated. These drugs, modifications of these drugs, and new drugs can also be used. Suggestions of specific modifications and strategies for designing analogs are presented. It is to be understood that these are just examples of drugs

SUBSTITUTE SHEET

which can be used in the present method and that this is not intended to be limiting in any way.

Inhibitors of Creatine Kinase

Drugs (antitumor, antiproliferative)

The pathways of biosynthesis and metabolism of creatine and creatine phosphate can be targeted in selecting and designing drugs which may reduce the velocity of the reaction catalyzed by creatine kinase. Drugs targeted to specific steps may rely on structural analogies with either creatine or its precursors. Novel creatine analogs differing from creatine by substitution, chain extension, and/or cyclization may be designed. The substrates of multisubstrate enzymes may be covalently linked, or analogs which mimic portions of the different substrates may be designed. Specifically, the inhibition of the creatine kinase reaction may be facilitated by a covalent link between adenosine 5'-triphosphate (ATP), adenosine 5'-diphosphate (ADP), or an analog of either, and creatine, or an analog, through the reactive termini of the molecules or via a spacer, such as $(CH_2)n$:

a)   Creatine-ADP   Creatine-ATP

b)   Creatine-R-ADP   Creatine-R-ATP

where R is a spacer, such as $(CH_2)_n$.

SUBSTITUTE SHEET

Replacement of the phosphate backbone or portions of
the backbone with methylene groups may facilitate
uptake by cells or increase stability. Variations
which reduce the net charge of such an analog may
also facilitate uptake by cells.

Additional Examples:

1)   Inhibitors of creatine kinase and analogs of
        creatine described by Kenyon and co-workers
        (Rowley, G.L. et al., J. Am. Chem. Soc.,
        93:5542-5551, (1971); McLaughlin, A.C. and M.
        Cohn, J. Biol. Chem., 247:4382-4388, (1972);
        Nguyen, A.C.K., "Synthesis and enzyme studies
        using creatine analogs", Thesis, Dept. of
        Pharmaceutical Chemistry, Univ. Calif.,San
        Francisco, (1983)) and others (Lowe, G. and
        Sproat, B.S., J. Biol. Chem., 255:3944-3951,
        (1980)); variants with appropriate
        modifications to enhance activity or uptake by
        cells.

SUBSTITUTE SHEET

Examples

a)   1,3 Dicarboxy-methyl-2-imino-imidazolidine

$$^-OOC-CH_2-N \overset{\oplus}{\underset{NH_2}{\diagdown}} N-CH_2-COOH$$

b)   2-Methyl-N,N'-dicarboxymethyl-imidazole

$$^-OOC-CH_2-N \overset{\oplus}{\underset{CH_3}{\diagdown}} N-CH_2-COO^-$$

c)   Epoxycreatine

2)   Compounds described by Walker and co-workers to inhibit creatine kinase (Roberts, J.J. and Walker, J.B., J. Biol. Chem., 260:13502−13508 (1985)).

3)   Small organic molecules which inhibit the purine metabolic enzyme, such as:

   − butanediones
       (e.g., 2,3-butanedione)
   − cyclopropane derivatives
   − salicylate derivatives
       (e.g., iodoacetamidosalicylate)

SUBSTITUTE SHEET

- iodoacetamide derivatives
    (e.g., N-(iodoacetamidoethyl)amino
        naphthalene-1-sulphonate,
    N-(4-iodoacetamidophenyl)amino
        naphthalene-1-sulphonate)
- benzene derivatives
    (e.g., 1-fluoro-2,4-dinitrobenzene,
        5,5'-dithiobis(2-nitrobenzoic acid))
- N-cyclohexyl-N-beta-methyl morpholinium salts

Derivatives or analogues of these molecules which will make them specific to CKB by linking them covalently to the substrates of CKB (i.e., creatine or ADP/ATP).

4)   Derivatives of ADP, ATP, such as:

a)   2',3'-dialdehyde derivatives of ADP, ATP;

b)   ATP-γ(N-(2-chloroethyl)-N-methyl) amide (a mustard derivative);

c)   imidazolides of AMP, ADP, ATP.

5)   A natural inhibitor in the serum of some patients, such as those with muscular dystrophy (which is a small dialyzable molecule of still unidentified origin).

SUBSTITUTE SHEET

6)   Compounds which uncouple of creatine kinase
      from the complex: adenylate
      kinase/translocase/creatine kinase.

7)   Some of the blockers used in resolving a
      myocardial infarction are thought to inhibit
      creatine kinase.

Inhibitors of Adenylate Kinase

1)   Multi-substrate inhibitors (Valentine, N., _et
      al._, _Am. J. Hematol._, _32(2)_:143-145 (1989);
      Gustav, E., _et al._, _J. Biol. Chem_.
      _248_:1121-1123 (1973)).

      a) P^1, P^5-Di(adenosine-5')pentaphosphate

      b)   The above compound in which methylene
            groups replace some or all of the
            phosphate groups, to facilitate uptake by
            cells.

      c) AP_4A, P_1, P_4-(diadenosine-5')tetraphosphate
            and its methylene substitutions.

2)   Elemental sulfur and its derivatives (Conner,
      J. and P.J. Russel, _Research Communications_,
      _113(1)_:348-352 (1983)).

3)   Adriablastin

SUBSTITUTE SHEET

(Toleikis, A.I. et al., Biokhimiya,
53(4):649-654 (1988)).

4) 5,5'-dithiobis-2(nitrobenzoate)
    (Declerck, P.J. and M. Muller, Comp. Biochem. &
    Physiol., 88(2):575-586 (1987)).

5) Adenosine, di-, tri-, tetraphosphopyridoxals
    (Yasami, T., et al., FEBS Lett., 229(2):261-264
    (1988)).

6) Potassium ferrate
    (Crivellone, M.D., et al., J. Biol. Chem.,
    260(5):2657-2661 (1985)).

7) 8-Azido-2'-O-dansyl-ATP
    (Chuan, H., et al., J. Bio. Chem.,
    264(14):7981-7988 (1989)).

Inhibitors of Adenosine Kinase

1) 5-iodotubercidin (from sponge of genus
    Echinodictyum)
    (Weinberg, J.M., et al., Am. J. Physiol.,
    254(3p+2) pF311-322, (1988)).

2) Two very potent inhibitors from marine sources
    4-Amino-5-bromo-pyrrolo[2,3-d] pyrimidine

    5'-Deoxy-5-iodotubercidin
    (from red alga Hypnea Valentiae)

(Davies, L.P., _et al_., <u>Biochem. Pharm.</u>,
<u>33(3)</u>:347-355 (1984)).

3) Clitocine and its derivatives
    (Moss, R.J., _et al_., <u>J. Med. Chem.</u>,
    <u>31(4)</u>:786-790 (1988)).

A link between transformation by DNA tumor
viruses and the increased activity and expression of
the brain isozyme of creatine kinase (CKB) has been
demonstrated, suggesting that high levels of CKB are
needed for the biochemical events triggered during
oncogenesis. Alterations in energy metabolism or
signal transduction mediated by CKB may be playing
an active role in these malignancies. A panel of
transformed and non-transformed cell lines were
established in culture and were tested for creatine
kinase activity. Cell lines which displayed high
creatine kinase activity were then analyzed to
determine the level of the brain isozyme of creatine
kinase (CKBB, see Example 1). Many transformed
cells expressed high levels of brain specific
creatine kinase.

A series of 15 creatine analogs or guanidino
compounds (including inhibitors of creatine kinase
and/or slow substrates, which, in the presence of
the natural substrate(s), act to reduce the velocity
of the reaction catalyzed by creatine kinase on its
natural substrate) were synthesized or purchased and
studied for their effects on the growth of several

SUBSTITUTE SHEET

tumor cell lines, especially on those which have
high levels of CKB.

As shown in Example 2, five of the creatine
analogs inhibited the growth of tumor cell lines in
culture. The drugs, homocyclocreatine,
cyclocreatine, 1-carboxymethyl-2-iminohexahydropyri-
midine, guanidinoacetate and carbocreatine, which
are slow substrates for creatine, showed different
patterns of activity against a panel of cell lines.
Cyclocreatine, the only analog tested which is
phosphorylated efficiently by creatine kinase, was
the only creatine analog that consistently showed
anti-proliferative activity specifically against
cell lines expressing high levels of CKB. Several
additional preparations of cyclocreatine were
synthesized, and then further purified by a series
of recrystallizations. These preparations retained
a similar level of anti-proliferative activity.

The patterns of activity for homocyclocreatine
and 1-carboxymethyl-2-iminohexahydropyrimidine were
similar in that the cell lines affected were the
same and the degrees of inhibition by either drug
were similar. The latter two drugs preferentially
inhibited the growth of the prostate and cervical
cell lines which are metastatic in origin as
compared with nonmetastatic prostate and cervical
cell lines. Furthermore, two non-transformed cell
lines, MRC-5 and Vero, which are tissue culture
versions of "normal" cell lines, were largely
unaffected by these two drugs, suggesting that they
may spare normal cells and may have a low toxicity

SUBSTITUTE SHEET

in vivo. However, the active component of these preparations is undefined, as both preparations have lost some anti-proliferative activity following four successive recrystallizations.

Guanidinoacetate strongly inhibited the growth of three colon tumor cell lines tested. (The data for guanidinoacetic acid is from two separate experiments and as such is not as extensive as that for the other three drugs.) The specificity of the homocyclocreatine preparation, the 1-carboxymethyl-2-iminohexahydropyrimidine preparation, and cyclocreatine for certain cell lines suggests that these drugs lack the indiscriminate toxicity observed with other anti-tumor therapies. In contrast, carbocreatine exhibited apparent non-specificity under the conditions of these studies. In addition, under the conditions used in the assay, and on the specific cell lines tested, ten other compounds (see Table 4) showed little or no activity (Example 3).

The present invention will be further illustrated by the following examples, which are not intended to be limiting in any way. The Materials and Methods following immediately were used in Examples 1-6.

Materials and Methods

Compounds

Compounds prepared for use in these studies included homocyclocreatine (1-carboxyethyl-2-iminoimidazolidine), cyclocreatine

SUBSTITUTE SHEET

(1-carboxymethyl-2-iminoimidazolidine),
1-carboxymethyl-2-iminohexahydropyrimidine,
guanidinoacetate (glycocyamine) and carbocreatine.
The synthesis of the homocyclocreatine preparation
was carried out as described by Roberts and Walker
(Roberts, J.J. and J.B. Walker, Arch. Biochem.
Biophys., 220:563-571 (1983)). The syntheses of
cyclocreatine and the 1-carboxymethyl-2-
iminohexahydropyrimidine preparation were carried
out as described by Griffiths and Walker (Griffiths,
G.G. and J.B. Walker, J. Biol. Chem., 251:2049-2054
(1976)). Guanidinoacetate was obtained from Sigma
Chemical Corp. (St. Louis, MO). The synthesis of
carbocreatine was carried out as described (Nguyen,
Ann Cae Khue, Ph.D. Thesis in Pharmaceutical
Chemistry, University of California, San Francisco,
CA, 1983).

Tumor Cell Lines:

A variety of tumor cell lines were obtained
from the American Type Culture Collection (ATCC,
Rockville, MD). The neuroendocrine-derived tumor
cell lines, such as the small cell lung carcinoma
cell line, were grown as cell suspensions in flasks
and were replated and fed twice a week. The other
cell lines were grown attached on plastic plates and
were replated at 90% confluency. All cell lines
were grown in media supplemented with fetal bovine
serum.

The properties of the cell lines used in these studies have been described (American Type Culture Collection (ATCC) Catalogue of Cell Lines and Hybridomas, 6th edition, Hay et al., Eds., 1988). Some of the the properties of the cell lines, including the origin, tumorigenicity, and markers, are summarized below.

Prostate Cell Lines

DU145: Prostate carcinoma, metastasis to brain, Human

Eagle's MEM, 90%; Fetal Bovine Serum (FBS), 10%

Isolated from a lesion in the brain of a patient with widespread metastatic carcinoma of the prostate and a three year history of lymphocytic leukemia. The cells have an epithelial-like morphology, are weakly positive for acid phosphatase, are not hormone sensitive, and form colonies in soft agar. Tumorigenic in nude mice. (Mickey, D.C. et al., Cancer Res. 37: 4049-4058 (1977); Stone, K.R. et al., Int. J. Cancer, 21: 274-281 (1978)).

LNCaP.FGC: Prostate adenocarcinoma, metastasis to lymph node, Human

RPMI 1640, 90%; FBS, 10%

Isolated from a needle aspiration biopsy of the left supraclavicular lymph node of a 50 year-old male with metastatic carcinoma of the prostate. The

SUBSTITUTE SHEET

cell line produces prostatic acid phosphatase and prostate specific antigen, and has androgen receptors. Tumorigenic in nude mice. (Models of Prostate Cancer, G.P. Murphy (ed.), pp. 115-132, Alan R. Liss, Inc., New York, 1980; Cancer Res. 43: 1809-1818, (1983); Cancer Genet. Cytogenet. 11: 399-404 (1984)).

PC-3: Prostate adenocarcinoma, Human
Eagle's MEM, 90%; FBS, 10%

Isolated from a grade IV prostatic adenocarcinoma from a 62 year-old male. The cell line has low acid phosphatase activity, grows in soft agar, and can grow in suspension. Tumorigenic in nude mice. (Invest. Urology 17:16-23, (1979); Cancer Res. 40: 524-534, (1980)).

Colon Cell Lines
SW48: Colon adenocarcinoma, Human
Leibovitz's L-15 Medium, 90%; FBS, 10%

Isolated from a grade IV colorectal adenocarcinoma, which encircled the bowel of an 82 year-old female. The cells have an epithelial-like morphology, and low levels of CEA. Tumorigenic in nude mice. (Leibovitz, A. et al., Cancer Res. 36: 4562-4569, (1976); Fogh, J. et al., J. Natl. Cancer Inst. 59: 221-226, (1977)).

SUBSTITUTE SHEET

<u>SW403</u>: Colon adenocarcinoma, Human
Leibovitz's L-15 Medium, 90%; FBS, 10%

Isolated from a grade III colorectal adenocarcinoma, which almost encircled the bowel of a 51 year-old female. The cells have an epithelial-like morphology, and produce carcinoembryonic antigen (CEA). Tumorigenic in nude mice. (Leibovitz, A. <u>et al</u>., <u>Cancer Res</u>. <u>36</u>: 4562-4569, (1976); Fogh, J. <u>et al</u>., <u>J. Nat. Cancer Inst</u>. <u>59</u>: 221-226 (1977)).

<u>SW1116</u>: Colon adenocarcinoma, Human
Leibovitz's L-15 Medium, 90%; FBS, 10%

Isolated from a grade II adenocarcinoma of the colon, which extended into the muscularis of a 75 year-old male. Melanosis was observed. The cells have an epithelial-like morphology, show brush borders, and produce high levels of CEA. (Leibovitz, A. <u>et al</u>., <u>Cancer Res</u>. <u>36</u>: 4562-4569, (1976)).

<u>Cervical Cell lines</u>
<u>C-33A</u>: Cervical carcinoma, Human
Eagle's MEM (with non-essential amino acids and sodium pyruvate), 90%; FBS, 10%

Isolated from a cervical cancer biopsy from a 66 year-old female. The cells have an epithelial-like morphology. Tumorigenic in nude mice.

SUBSTITUTE SHEET

(Auersperg, N., <u>J. Natl. Cancer Inst</u>. <u>32</u>: 135-148,
(1964)).

<u>CaSki</u>: Cervical epidermoid carcinoma, Human
RPMI 1640, 90%; FBS, 10%

Isolated from an epidermoid carcinoma of the
cervix metastatic to the mesentery of the small
bowel of a 40 year-old patient. The cells express
tumor-associated antigen and produce the beta
subunit of human chorionic gonadotropin. (Pattillo,
R.A. <u>et al</u>., <u>Science</u> <u>196</u>: 1456-1458, (1977)).

<u>SiHa</u>: Cervical squamous carcinoma, Human
Eagle's MEM (with non-essential amino acids and
sodium pyruvate), 90%; FBS, 10%

Isolated from a primary tissue surgical sample
from a 55 year-old patient. Epithelial-like
morphology. Forms tumors in nude mice. (Friedl, F.
<u>et al</u>., <u>Proc. Soc. Exp. Biol. Med</u>. <u>135</u>: 543-545,
(1979)).

<u>HeLa</u>: Cervical epitheloid carcinoma, Human
Eagle's MEM with non-essential amino acids and
Earle's BSS, 90%; FBS, 10%

Isolated from a cervical carcinoma of a 31
year-old (<u>Cancer Res</u>., <u>12</u>: 264, (1952)).
Epithelial-like morphology.

SUBSTITUTE SHEET

<u>ME-180</u>: Cervical epidermoid carcinoma, Human
McCoy's 5a medium, 90%; FBS, 10%

Isolated from an omental metastasis of a
rapidly spreading cervical carcinoma from a 66
year-old (Sykes, <u>et al</u>., <u>J. Nat. Cancer Inst</u>. <u>45</u>:
107-122, (1970)). The tumor was a highly invasive
squamous cell carcinoma and shows epithelial-like
morphology in culture. Tumorigenic in nude mice.

<u>Lung Cell Lines</u>
<u>NCI-H69</u>: Small cell carcinoma of the lung, Human
RPMI 1640, 90%; FBS, 10%

Isolated from the pleural fluid of a 55
year-old male with small cell carcinoma of the lung.
Forms colonies in soft agar and grows in suspension.
Has small cell carcinoma morphology and APUD
characteristics. Tumorigenic in nude mice.
(Gazdar, A. <u>et al</u>., <u>Cancer Res.</u> <u>40</u>: 3502-3507,
(1980)).

<u>MRC-5</u>: Diploid non-transformed lung cell line,
          Human
Eagle's Basal Medium with Hanks' BSS, 90%; FBS, 10%

Derived from normal lung tissue of a 14
week-old fetus. Fibroblast-like morphology.
(<u>Nature</u> <u>277</u>: 168-170, (1970)).

SUBSTITUTE SHEET

Bone Cell Lines
U-2 OS: Primary osteogenic sarcoma, Human
McCoy's 5a medium, 85%; FBS, 15%

Derived from a sarcoma from the tibia of a 15 year-old. Epithelial-like morphology (Int. J. Cancer, 2: 434-447, (1967)).

Saos-2: Primary osteogenic sarcoma, Human
McCoy's 5a medium, 85%; FBS 15%

Isolated from an 11 year-old. This line has an epithelial-like morphology consistent with osteogenic sarcoma. The cells do not form tumors in nude mice. (In: Human Tumor Cells In Vitro, pp. 115-159, J. Fogh, (ed.), Plenum Press, New York, (1975))

Kidney Cell Lines
293: Transformed primary embryonal kidney, Human
Eagle's MEM, 90%; horse serum, 10%

The 293 cell line was derived from primary human embryonal kidney cells transformed with sheared DNA from human adenovirus type 5. (J. Gen. Virol., 36: 59-72, (1977)).

Vero: Normal kidney, African Green Monkey
Medium 199, 95%; FBS, 5%

Initiated from the kidney of a normal adult African Green Monkey (Yasumura, Y. and Kawakita, Y.,

Nippon Rinsho, 21: 1209, (1963)). Fibroblast-like morphology.

Embryonal Cell Lines
BALB/3T3: Embryonal tissue, Mouse
Dulbecco's modified Eagle's medium, 90%; calf serum, 10%

Isolated from disaggregated mouse embryos. The line is non-tumorigenic, and shows contact inhibition. (Aaronson, S.A. and Todaro, G.T., J. Cell Physiol. 72: 141-148, (1968)).

F9: Embryonal carcinoma, Mouse
Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 85%; FBS, 15%

Initiated from a testicular teratocarcinoma of a mouse (Bernstine et al., Proc. Natl. Acad. Sci. USA, 70: 3899-3903, (1973)). The cell line can be induced to differentiate into parietal endoderm under certain culture conditions.

Proliferation Assays:
The rate of incorporation of thymidine into DNA was adopted as a measure of cell proliferation. To test the effect of several creatine analogs (inhibitors of creatine kinase and/or slow substrates, referred to here as drugs), on the growth of cell lines, the cells were harvested and replated in either 24 or 96 well plates at an

appropriate density. The next day, drugs were added
at the indicated concentration. Tritiated thymidine
(^{3}H-thymidine; Amersham) was added to a final
concentration of 2 μCi/ml one hour to twenty-four
hours before the cells were harvested, depending on
the length of the experiment. Treated cells were
harvested by one of two methods. In the first
method, cells were lysed by the addition of 10%
trichloroacetic acid or 10% sodium dodecylsulfate.
Precipitated DNA was removed by centrifugation and
was blotted onto 3MM filter paper. Filters were
washed sequentially with methanol and acetone,
dried, then placed in vials containing Ready Safe
liquid scintillant (Beckman) and counted in a
Beckman LS 31-33 T liquid scintillation counter.

In the second method, media was removed by
aspiration or inversion and the cells were incubated
for five minutes at 37°C in 100 μl of trypsin (2.5%,
Sigma Chemical Corp., St. Louis, MO) to detach the
cells. Cells were harvested with a Skatron cell
harvester, collected on 102 x 258 mm glass fiber
filter paper (Pharmacia #1205-401), sealed in a bag
containing Betaplate liquid scintillant (LKB) and
were counted in a 1205 Betaplate liquid
scintillation counter to determine the associated
radioactivity. All samples for each time point were
taken in duplicate or triplicate. To obtain values
for growth as a percent of control for drug treated
cultures, the incorporation of ^{3}H-thymidine in the
presence of drug was divided by the incorporation of

^{3}H-thymidine in the absence of drug and was then multiplied by a factor of 100.

Protein Extracts from Tumor Cells:

Treated or untreated cell lines were washed two to three times with phosphate buffered saline (PBS). Adherent cells were then scraped from the plates in 1 ml of PBS, transferred to a microfuge tube and centrifuged to pellet cells. Non-adherent cultures were first transferred to 15 ml conical tube and centrifuged at 1000 rpm for 5 min. The pellet was resuspended in 5 ml of PBS and centrifuged and the procedure was repeated. This washed pellet was then resuspended in 1 ml of PBS, transferred to a microfuge tube and centrifuged to pellet cells. The resulting cell pellets were resuspended in 50 to 200 μl of 0.2M Tris/0.1M NaCl and were lysed by three cycles of freeze-thawing. Particulate matter was removed by centrifugation and the supernatant was used for creatine kinase enzyme assays, creatine kinase isozyme electrophoresis assays, or to meausre total protein levels of cell extracts. Protein content of cellular extracts was determined using the Bio-Rad Protein Assay (Bio-Rad, #500-0006), a dye-binding assay based on the differential change in absorbance of Coomassie Brillant Blue G-250 from 465 nm to 595 nm in response to binding to protein at various concentrations.

Creatine Kinase Activity:

Total creatine kinase activity was determined
in a coupled reaction using Sigma's creatine kinase
kit CK10, where the production of ATP by creatine
kinase is coupled to the reduction of nicotinamide
adenine dinucleotide phosphate (NADP). The progress
of the reaction was monitored spectrophotometrically
at 340nm. The coupled reactions are:

$$\text{Creatine phosphate + ADP} \underset{}{\overset{\text{CK}}{\rightleftharpoons}} \text{Creatine + ATP}$$

$$\text{ATP + Glucose} \underset{}{\overset{\text{HK}}{\rightleftharpoons}} \text{Glucose-6-phosphate + ADP}$$

$$\text{Glucose-6-phosphate + NADP} \underset{}{\overset{\text{G6PD}}{\rightleftharpoons}} \text{6-phosphogluconate + NADPH}$$

CK = Creatine kinase
HK = Hexokinase
G6PD = Glucose-6-phosphate dehydrogenase

The coupled reactions were carried out so that
the reaction catalyzed by creatine kinase was the
rate limiting reaction. Hexokinase and G6PD were in
excess. Therefore, the rate of reduction of NADP to
NADPH was proportional to creatine kinase activity.

Another test was adopted to assess the
proportion of total creatine kinase activity
attributable to the brain isoenzyme. The enzyme
mixture or cell extract was fractionated by
electrophoresis on a 0.8% agarose gel at 90
volts/hr. The gel was then immersed in the

constituents of the coupled reaction described above, with appropriate salts. A colored visible band is generated in the gel at the locations of enzyme activity (Creatine Kinase Kit #715AM, Sigma Chemical Corp.). The migration of each CK isozyme is different, allowing the bands and the activities associated with each isozyme to be distinguished from one another. One can locate the brain isozyme in the gel by running a sample of pure CKBB as a marker.

Example 1

Level of Creatine Kinase Brain Isozyme Activity in Different Non-Transformed Tumor Cell Lines

Although transformation of cells is associated with alterations in gene expression, very little is known about the cellular processes affected in this transformation process. An important link between the transforming potential of viral oncogene products and the expression of CKB has been demonstrated. To further study the role of creatine kinase in malignancy a panel of transformed and non-transformed cell lines were purchased from the ATCC, were established in culture and were tested for CK expression. Cells were harvested at confluency and were extracted of their protein. To determine total creatine kinase (CK) activity, the protein extracts were assayed spectrophotometrically using coupled reactions (Sigma Kit #49 UV). The

extracts were also fractionated on 0.8-1.0% agarose
gels to separate the CK isoenzymes, and were assayed
for CK activity directly in the gel, using Sigma Kit
#715 AM. The values determined for total creatine
kinase activity, corrected for protein concentration
(ΔA_{340}/min/A_{590} x 100) for the cell lines listed
above are listed in Table 1. It is concluded that
many tumor cells in this sampling (lung-, cervical-,
and prostate-derived tumor cell lines) expressed a
high level creatine kinase, while the
non-transformed cells (MRC-5, Vero, BALB/c3T3, and
F9) showed a low level of creatine kinase.

The CK isozyme patterns generated in an agarose
gel by the coupled reaction and staining procedure
described above, were determined for extracts from
several tumor cell lines, including small cell lung
carcinoma line NCI-H69, prostate carcinoma lines
LNCaP.FGC and DU 145, and cervical carcinoma line
C-33A. Pure CKBB (brain isozyme), CKMM (muscle
isozyme), and CKMB (cardiac isozyme) were run on the
gel as controls to indicate the locations of each
isozyme in the gel. It was clear from this analysis
(data not shown) that brain creatine kinase is the
predominant isozyme and thus represents the majority
of the creatine kinase activity of these tumor cell
lines. These results are consistent with the
suggestion that an increased level of expression of
the creatine kinase B isozyme is a characteristic
alteration in cellular gene expression that occurs
during transformation and one that may contribute to
the transformed phenotype.

SUBSTITUTE SHEET

TABLE 1
Creatine Kinase Activity in Different
Tumor Cell Lines

Tissue	Cell Line	$\Delta A_{340}/min/A_{590} \times 100$
Lung	MRC-5	3
	NCI-H69	50
Cervical	C-33A	10
	CaSki	0.5
	SiHa	2
	HeLa	10
	ME180	38
Bone	U-2 OS	1
	Saos-2	2
Kidney	Vero	<1
	293	27
Prostate	PC-3	1
	LNCaP.FGC	30
	DU 145	15
Colon	SW1116	2
	SW403	6
	SW48	3
Embryonal	BALB/c3T3	2
	F9	<1

Example 2

Inhibition of DNA Synthesis in Tumor Cells by Inhibitors of Creatine Kinase

The ability of a transformed cell to proliferate indefinitely allows a tumor cell to be cloned and passaged in tissue culture. In vitro, the growth of a population of tumor cells can be quantified through the monitoring of incorporation of ^{3}H-thymidine into the DNA of the growing cells. This growth assay creates a convenient means to measure the potential antitumor activity of a compound. Compounds that inhibit the incorporation of ^{3}H-thymidine into DNA inhibit DNA synthesis and thereby, inhibit cell proliferation. All such compounds are candidate anticancer drugs. Thus, to determine the potential anticancer activity of inhibitors of creatine kinase, multiple creatine analogs were synthesized and were tested for their ability to inhibit the proliferation of established lines of tumor cells in vitro.

Compounds

Homocyclocreatine (1-carboxyethyl-2-imino-imidazolidine), cyclocreatine (1-carboxymethyl-2-iminoimidazolidine), and 1-carboxymethyl-2-imino-hexahydropyrimidine are cyclic derivatives of creatine. Carbocreatine (3-amino-butyric acid) differs from creatine in that one of the guanidino nitrogens of creatine has been substituted with a

SUBSTITUTE SHEET

carbon. Guanidino acetate is an analog of creatine that lacks a methyl substituent.


<u>Creatine</u>

$$\begin{array}{c} \oplus \end{array} \quad \begin{array}{c} NH_2 \\ \diagdown \\ \diagup \\ NH_2 \end{array} C{-}N{-}CH_2{-}COO^{-} \quad \overset{CH_3}{\underset{}{|}}$$

<u>Homocyclocreatine</u>
(1-carboxyethyl-2-iminoimidazolidine)

$$\oplus \quad HN \underset{}{\overset{NH_2}{\diagup}} N{-}CH_2{-}CH_2{-}COO^{-}$$

Homocyclocreatine was shown to be a poor substrate for rabbit muscle creatine kinase, and was reported to react with creatine kinase 10,000-fold more slowly than creatine. In the reverse reaction, at pH 7.0, homocyclocreatine-phosphate (0.2 mM homocyclocreatine-P) was 200,000-fold less active than creatine phosphate as a substrate for rabbit muscle creatine kinase (Roberts, J.J. and J.B. Walker, <u>Arch. Biochem. Biophys</u>. <u>220</u>: 563-571 (1983)).

SUBSTITUTE SHEET

Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine)

    Cyclocreatine is similar in structure to
homocyclocreatine, differing only by the absence of
one methylene group. Cyclocreatine is a better
substrate for creatine kinase in vitro than
homocyclocreatine, and reacts 1500-fold faster. In
the reverse direction, the rate of reaction with
creatine kinase in vitro for cyclocreatine-phosphate
(cyclocreatine-P) is about 1000-fold faster than
that for homocyclocreatine-P (Roberts, J.J. and J.B.
Walker, Arch. Biochem. Biophys., 220:563-571
(1983)). McLaughlin et al. reported a relative
maximal velocity for reaction of rabbit skeletal
muscle creatine kinase with cyclocreatine at 1°C
that was 90% that observed with creatine, and a K_m
of 25 mM, only 5-fold higher than that creatine
(McLaughlin, A.C. et al., J. Biol. Chem.,
247:4382-4388 (1972)). Therefore, under these
conditions in vitro, the Vmax/Km ratio for
cyclocreatine in the forward reaction is
approximately one-fifth that of creatine.

    The phosphorylated compound cyclocreatine-
phosphate is structurally similar to creatine-
phosphate; however, the phosphorous-nitrogen bond of
cyclocreatine-phosphate is more stable than that of
creatine-phosphate. Cyclocreatine-phosphate

SUBSTITUTE SHEET

(3-phosphoryl-1-carboxy-methyl-2-iminoimidazolidine) has a Gibbs free energy of hydrolysis which is approximately 2 kcal/mol below that of creatine phosphate (N-phosphorocreatine) and about 1 kcal/mol above that of ATP. At pH 7 (37°C) in the reverse reaction catalyzed by creatine kinase, the V_{max}/K_m ratio for cyclocreatine-phosphate is approximately 160-fold lower than for creatine-phosphate (Annesley, T.M. and Walker, J.B., J. Biol. Chem., 253: 8120-8125 (1978); Annesley, T.M. and Walker, Biochem. Biophys. Res. Commun. 74: 185-190 (1977)). Because cyclocreatine-phosphate binds to the enzyme creatine kinase with a K_m similar to that of creatine phosphate, yet turns over about 100 times more slowly than does creatine phosphate, cyclocreatine phosphate acts as a competitive inhibitor of creatine kinase. In addition, as cyclocreatine phosphate accumulates in cells, the level of creatine phsphate is suppressed, and hence, a new phosphagen pool is created which is not utilized efficiently in phosphoryl transfer functions.

1-Carboxymethyl-2-iminohexahydropyrimidine (6-CCr)

1-Carboxymethyl-2-iminohexahydropyrimidine (6-CCr) is an analog of creatine, in which two of

the nitrogens are joined to form a six-membered
ring. 6-CCr differs from cyclocreatine in that the
cyclic portion of the molecule has six members
instead of five members.

The initial rate of reaction with rabbit muscle
creatine kinase of 6-CCr was reported to be 400
times slower than the initial rate of reaction of
cyclocreatine (Rowley, G.L. et al., J. Am. Chem.
Soc., 93:5542-5551 (1971)). Another group reported
no measurable activity of creatine kinase for this
compound (McLaughlin, A.C. et al., J. Biol. Chem.,
247:4382-4388 (1972)).

Guanidinoacetate

$$\oplus \quad \begin{array}{c} H_2N \\ \\ H_2N \end{array} C-\overset{\overset{\displaystyle H}{|}}{N}-CH_2-COO^-$$

Guanidinoacetate is a biosynthetic precursor of
creatine and is a moderately active substrate for
creatine kinase. McLaughlin and colleagues reported
a maximal velocity of reaction with rabbit muscle
creatine kinase 10% that of creatine, and a K_m about
14-fold below that for creatine (McLaughlin, A.C. et
al., J. Biol. Chem., 247: 4382-4388 (1972)). Thus,
while guanidinoacetate is a better substrate for the
enzyme than homocyclocreatine or 6-CCr, it is a
poorer substrate than cyclocreatine in the forward
reaction.

SUBSTITUTE SHEET

<u>Carbocreatine</u>

$$\oplus \overset{NH_2}{\underset{NH_2}{\diagdown}}C - \overset{\overset{CH_3}{|}}{CH} - CH_2 - COO^-$$

Carbocreatine is an analog of creatine in which one of the guanidino nitrogens is replaced with a carbon. Nguyen reported that the initial rate of the reaction with rabbit muscle creatine kinase and carbocreatine was less than 1% of that of creatine. Carbocreatine-phosphate was shown to be more stable than creatine-phosphate in vitro (Nguyen, Ann Cae Khue, Ph.D. Thesis in Pharmaceutical Chemistry, University of California, San Francisco, CA, 1983).

<u>Homocyclocreatine Inhibits the Proliferation of DU 145 Cells in a Dose-Dependent Manner</u>

The results of an experiment illustrating the antiproliferative effect of the homocyclocreatine preparations is shown in Figure 8. In this particular experiment, the effect of a homocyclocreatine preparation on the DNA synthesis of the DU 145 cell line, derived from a prostatic carcinoma which expresses a high level of creatine kinase BB, was determined. The concentration of drug was varied from 0 mM to 10 mM.

DNA synthesis was monitored under each regimen by measurement of incorporation of ^{3}H-thymidine once a day for 5 days. Each day after initial drug addition, the media was changed and the drug was

replenished. Control cells received new media with
no drug addition. Figure 8 shows a plot of the
incorporation of ^{3}H-thymidine as percent of the
untreated control versus the concentration of
homocyclocreatine for 1, 2, 3, 4 or 5 days of
exposure to the drug. It is clear that there is
both a dose- and time-related response to
homocyclocreatine. As the concentration of or
duration of exposure to homocyclocreatine increased,
the % growth of DU 145 cells decreased.

In addition, from these curves, the ID50 or the
concentration at which 50% inhibition of growth is
reached for each period of treatment (1-5 days) can
be determined. The values for the ID50 range from
3.0 mM homocyclocreatine for one day of treatment to
0.7 mM homocyclocreatine for five days of treatment.
Thus 50% inhibition of growth of prostate tumor cell
line DU 145 was achieved by exposure to approxi-
mately 1.0 mM homocyclocreatine for a period of five
days.

Effects of Creatine Kinase Inhibitors on DNA
Synthesis of Normal and Multiple Tumor Cell Lines

Given the dose-related response observed for
homocyclocreatine against DU 145 cells,
homocyclocreatine preparations and other inhibitors
of creatine kinase were assayed for
antiproliferative activity against a panel of cell
lines. Eighteen different cell lines were treated
with homocyclocreatine (HcCr), cyclocreatine (CCr),
and 1-carboxymethyl-2-iminohexahydropyrimidine
(6-CCr) and guanidinoacetate. The cell lines used

in these experiments included the non-transformed
lung fibroblast MRC-5 cell line, the immortal mouse
embryo cell line BALB/c3T3, four human cervical
carcinoma cell lines (C-33A, CaSki, SiHa, and HeLa),
two human osteogenic sarcomas (U-2 OS and Saos-2), a
non-transformed African Green Monkey kidney cell
line (Vero), an adenovirus (type 5) transformed
human primary embryonal kidney call line (293),
three human prostate carcinoma cell lines (PC-3,
LNCaP.FGC, and DU 145), three human colon
adenocarcinomas (SW1116, SW403, and SW48), a human
small cell lung carcinoma cell line (NCI-H69), and
the F9 mouse embryonal carcinoma cell line.

In the first set of experiments, the cell lines
were treated with 0, 1, 2, or 4 mg/ml drug for five
days, and were assayed for growth by incorporation
of ^{3}H-thymidine. In the second set of experiments,
the same eighteen cell lines were treated with 4
mg/ml drug for five days before assaying for growth.

The data from both sets of experiments are
summarized in Table 2. In some cases, values from a
third experiment, using a similar protocol, are
included in the table (in parentheses). For each of
the eighteen cell lines in Table 2, the inhibition
of growth by each drug at 4 mg/ml is recorded as a
percent of the untreated control (4 mg/ml ≈ 24 mM
for each drug).

SUBSTITUTE SHEET

TABLE 2

Effect of Drug on ^{3}H-Thymidine Incorporation
(Incorporation as a % of Untreated Control)

Tissue	Tumor Type	(CK activity)	Cell Line	#236 HcCr	#216 6-CCr	#229 CCr	#237 GA
Lung	Non-transformed (Human)	3	MRC-5	102 84 (112)	116 118 (114)	32 24	75 --
	Small Cell Carcinoma (Human)	50	NCI-H69	28	29	35(1mg/ml)	81
Cervical	Carcinoma (Human)	10	C-33A	32 63	40 68	17 26	374 --
	Epidermoid Carcinoma (Human)	0.5	CaSki	9 5 (4)	25 5 (2)	33 68	86 --
	Squamous Carcinoma (Human)	2	SiHa	56 92	48 83	7 20	131 --
	Epitheloid Carcinoma (Human)	10	HeLa	83 102	60 65	33 37	89 --
Bone	Osteogenic Sarcoma (Human)	1	U-2 OS	101 0.06	55 10	69 0.02	147 --
	Osteogenic Sarcoma (Human)	2	Saos-2	64 0.03	825 27	7 0.02	49 --
Kidney	Normal Kidney (African Green Monkey)	1	Vero	112 120	117 119	-- 79	97 --

SUBSTITUTE SHEET

TABLE 2 (cont)

Tissue	Tumor Type	(CK activity)	Cell Line	#236 HcC	#216 6-CCr	#229 CCr	#237 GA
	Ad 5 Transformed Embryonal (Human)	27	293	9 4	19 2	-- 11	63 --
Prostate	Adenocarcinoma (Human)	1	PC-3	109 82	88 87	34 26	93 --
	Adenocarcinoma, Lymph node metastasis (Human)	30	LNCaP.FGC	85 0.04	14 13	0.05 0.03	54 --
	Carcinoma, brain metastasis (Human)	15	DU 145	7 0.03	12 5	24 0.02	108 --
Colon	Adenocarcinoma (Human)	2	SW1116	74 0.04	80 102	0.34 0.14	5 --
	Adenocarcinoma (Human)	6	SW403	1 0.47	91 0.5	0.12 0.17	9 --
	Adenocarcinoma (Human)	3	SW48	63 72	84 74	0.64 12	4 --
	Adenocarcinoma (Human)	2	BALB/c3T3	3 6 (9)	11 7 (39)	110 59	4 --
Embryonal	Embryo (Mouse) Embryonal carcinoma (Mouse)	1	F9	11 217	21 431	57(1mg/ml) 7	204 --

Effect of Drug on ^{3}H-Thymidine Incorporation (Incorporation as a % of Untreated Control)

SUBSTITUTE SHEET

In some cases, the percent inhibition of growth of a cell line by a given drug appears to vary significantly. Variations in the culture conditions may explain these fluctuations. For example, in the second experiment with the Saos-2 osteogenic sarcoma line, the cells appeared to be dying independent of the administration of drug. The LNCaP.FGC prostate cells tended to grow in clumps and become nonadherent, leading to inconsistency in harvesting of the cells. Further, because healthy LNCaP.FGC cells are somewhat nonadherent, it is difficult to visually identify generally unhealthy cells and distinguish these from cells actually inhibited by drug. The F9 teratocarcinoma cells also show variation, possibly due to fluctuations in pH or to the fact that the cells are grown on a gelatin matrix and detach from the substratum easily. The incorporation of ^{3}H-thymidine by the untreated F9 cells was inconsistent. Lastly, some of the fluctuation in values for the colon cell lines may result from acidification of the medium, which is not buffered by sodium bicarbonate.

The values are quite consistent in many cases. Furthermore, by conducting multiple experiments one can identify the effect of drug apart from artifactual fluctuations. For example, homocyclocreatine and 6-CCr reproducibly inhibited the growth of DU 145. Similarly, cyclocreatine strongly and reproducibly inhibited the growth of the cervical carcinoma line ME-180 (see below) as well as all a series of colon carcinoma cell lines.

SUBSTITUTE SHEET

An example of the dose-response of colon
carcinoma cell lines to cyclocreatine is shown in
Figure 9. The effect of cyclcocreatine on five
colon carcinoma cell lines obtained from the ATCC
(SW1116, ATCC CCL 233; SW48, ATCC CCL 231; SW620,
ATCC CCL 227; Caco-2, ATCC HTB 37 (CACO2); and WiDr,
ATCC CCL 218, (WIDR)) was determined. In this case,
each cell line was incubated for 7 days in the
presence of 0.0 mM, 3.5 mM, 7.0 mM, 14.0 mM, 28.0
mM, 42.0 mM, 56.0 mM or 70.0 mM cyclocreatine.
Figure 9 shows a histogram illustrating
incorporation of ^{3}H-thymidine (CPM) versus the
concentration of cyclocreatine for each cell line.
As the concentration of cyclocreatine increases, the
incorporation of ^{3}H-thymidine into the DNA of each
cell line decreases. This clear dose-related
response establishes the anti-proliferative effect
of cyclocreatine against these colon cell lines.

From these examples and from the results of
many other experiments, it is clear that
cyclocreatine and the homocyclocreatine and
1-carboxymethyl-2-iminohexahydropyrimidine
preparations can inhibit the growth of a variety of
tumor cell lines in vitro. In contrast; none of the
compounds has a strong or reproducible effect
against the non-transformed cell line Vero.
Similarly, the non-transformed lung fibroblast MRC-5
is unaffected by HcCr and 6-CCr and weakly affected
by cyclocreatine, suggesting that normal tissues may
tolerate homocyclocreatine, 6-CCr, or cyclocreatine
at doses not tolerated by tumor tissue.

SUBSTITUTE SHEET

Trends of Anti-Proliferative Activity of Creatine Kinase Inhibitors

The comparison of results from multiple experiments such as those described above reveals several trends. Figure 10 summarizes the results of a series of proliferation assays using a representative value from one such experiment for each of 15 of the cell lines tested above and one additional cell line, ME-180, which is derived from a cervical carcinoma. In Figures 10A-10D, the height of the bars represents the incorporation of ^{3}H-thymidine as a percent of the corresponding untreated control for cells treated with 4 mg/ml of a homocyclocreatine preparation (Figure 10A, HcCr), 4 mg/ml of a 1-carboxymethyl-2-iminohexa-hydropyrimidine preparation (Figure 10B, 6-CCr), 4 mg/ml cyclocreatine (Figure 10C), or 4 mg/ml guanidinoacetate (Figure 10D, GA). The trends of anti-proliferative activity highlighted by these figures is summarized below.

First, the HcCr and 6-CCr preparations showed a nearly identical pattern of specificity, such that lines that were strongly affected by the former were strongly affected by the latter. Similarly, the lines that were marginally affected by one drug were only marginally affected by the other. Although the HcCr, 6-CCr, and cyclocreatine preparations all had a minimal effect on DNA synthesis of non-transformed cells, cyclocreatine showed a different spectrum of activity than the HcCr and 6-CCr preparations against the panel of cell lines.

SUBSTITUTE SHEET

The sensitivity of colon cell lines to inhibition by cyclocreatine documented in Figure 9 is evident in Figure 10C as well. Another trend of particular interest is emphasized in Figure 11. Figure 11 shows the growth as a percent of control for five cervical lines treated with HcCr, 6-CCr or CCr. The C-33A, HeLa and SiHa lines are derived from primary tumors, while the CaSki and ME-180 lines are derived from metastases. The HcCr and 6-CCr preparations showed preferential inhibition of the cervical metastatic cell lines relative to the non-metastatic lines. In contrast, CCr did not show this preference for metastatic cell types. Note that the HcCr and 6-CCr preparations also tended to inhibit the growth of the metastatic prostate lines DU 145 (brain metastasis) and LNCaP.FGC (lymph node metastasis), although the results for the LNCaP.FGC line were less reproducible. Again, the non-metastatic prostate line, PC-3, was not strongly inhibited by the HcCr or 6-CCr preparations.

The metabolism of metastatic cells may differ from that of non-metastatic cells. Thus, the metastatic lines may be more susceptible to inhibition of a function that is essential, though not necessarily unique, to those cells. In addition, the function or functions inhibited in the metastatic lines may also be necessary to or involved in the process of metastasis. The HcCr and 6-CCr preparations could be affecting the processes that control, activate, or are required for metastasis, either directly or indirectly. The

SUBSTITUTE SHEET

drugs could be administered alone or in combination
with other drugs or therapies to prevent metastasis.
They may also be particularly effective in killing
tumor cells or reducing the growth of tumors in
aggressive or late stage disease (especially in
prostatic and cervical disease), where metastasis
has already taken place.

Usually, late stage prostatic cancers are
unresponsive to hormone therapy. In fact, the DU
145 cell line does not respond to hormone therapy.
Thus, drugs which inhibit growth of the DU 145 cell
line, such as the homocyclocreatine and
1-carboxymethyl-2-iminohexahydropyrimidine
preparations could provide effective therapies for
these untreatable tumors. Identification of the
site of action of the drugs may shed light on the
processes of metastasis and may suggest other
methods of interfering with metastasis.

It is important to emphasize that the MRC-5 and
Vero cell lines are largely unaffected by the HcCr
and 6-CCr preparations. The MRC-5 and Vero lines
are tissue culture versions of "normal" cell lines.
Thus, HcCr and 6-CCr may also spare normal cells,
suggesting they may have low toxicity in an
individual.

Another important trend observed in multiple
experiments is that cyclocreatine inhibited the
growth most consistently of tumor cells expressing
the highest levels of creatine kinase. For example,
ME-180, 293, and LNCaP.FGC cells, all expressing
very high levels of creatine kinase (see Table 1),

SUBSTITUTE SHEET

are strongly affected by cyclocreatine. For HcCr
and 6-CCr on the other hand, no such obvious
correlation between creatine kinase activity and
growth inhibition is seen.

The precise mode and site of action for each of
these three preparations (CCr, HcCr, 6-CCr) is not
known. However, it is noted in light of the
different specificity (i.e., different pattern of
cell lines affected) of the HcCr and 6-CCr
preparations on the one hand, and that of the
cyclocreatine preparation on the other hand, that
HcCr and 6-CCr are distinct from cyclocreatine in
that they are very poor substrates for creatine
kinase in the forward reaction and are thus
phosphorylated very slowly. It is therefore
possible that the two classes of compounds are
acting through a different mechanism.

In view of this possibility, it is interesting
to note that the HcCr and 6-CCr preparations do not
retain full anti-proliferative activity upon
multiple recrystallizations of the major product of
the referenced synthetic protocols, while
cyclocreatine does retain complete activity through
multiple recrystallizations of the major product.
Although it is most probable that cyclocreatine is
the active component of its preparation, it is
possible that the active component of the HcCr and
6-CCr preparations is not the expected creatine
analog. The cited literature preparations for HcCr
and 6-CCr do lead reproducibly, however, to the
synthesis of the anti-proliferative activity

SUBSTITUTE SHEET

illustrated here. Three preparations of HcCr and
two preparations of 6-HcCr have produced similar
patterns of activity. Therefore, as used herein,
"homocyclocreatine" and "1-carboxymethyl-2-
iminohexahydropyrimidine" are used to refer to
preparations containing homocyclocreatine and
1-carboxymethyl-2-iminohexahydropyrimidine,
respectively, the preparations having the activity
exemplified and claimed herein and which were
obtained from the referenced source or made by the
synthetic methods referenced herein.

Guanidinoacetate showed a third pattern of
inhibition against the panel of cell lines. In the
case of guanidinoacetate, two series of experiments
to date have shown strong inhibition of the growth
of all three colon lines and of the BALB/c3T3 line.
The remainder of the lines were largely unaffected
by the drug. Again, the mode of action of
guanidinoacetate is not known. Because changes in
the pH of the medium under the culture conditions
were not quantified, data for the colon cell lines
should be interpreted cautiously.

Carbocreatine, tested in similar experiments,
inhibited the growth of both transformed and
non-transformed cell lines tested to approximately
the same extent (data not shown). The calculated
ID50 of carbocreatine for these lines was about 1
mM. In addition there was no correlation of the
anti-proliferative effect of the compound with the
creatine kinase activity of cell line being tested.
These results suggest that this drug may not have

SUBSTITUTE SHEET

the desired specificity for tumor cells and may not
be functioning through creatine kinase.

The differences between cell lines in suscepti-
bility to a given drug may reflect differences in
the cause or severity of transformation or other
properties of the cell lines, for example. The
tendency of the four drugs (HcCr, 6-CCr, CCr and GA)
to inhibit a particular subset of lines, in essence
displaying selective killing, may also result in
reduced toxicity in vivo.

Example 3

Guanidino Compounds with Little or No Effect on Tumor Cell Growth

Ten additional guanidino (i.e., creatine and
analogs) compounds were tested for their ability to
inhibit growth of a number of cell lines. The
structures of the ten compounds tested, references,
and sources of purchase are listed in Table 4. In
these experiments, the cell lines were exposed to a
drug at concentrations from 1 mg/ml to 4 mg/ml for a
period of five days. After five days, cells were
washed to remove the drug, and growth was assayed by
incorporation of ^{3}H-thymidine into DNA.

At a concentration of 1 mg/ml, after five days
of exposure to drug and under the conditions of the
assay, these ten guandidino compounds showed little
or no effect on the growth of the cell lines. In
most cases, only modest effects on cell growth were

observed with the drugs at a concentration of 4 mg/ml (Table 5). In addition, β-guanidino-propionic acid and N-methyl-hydantoic acid inhibited the growth of the non-transformed MRC-5 cell line more strongly than they inhibited growth of many of the transformed cell lines, suggesting that these drugs may not have the desired specificity for tumor cells.

Although colon cell lines SW1116 and SW48 appeared to be strongly inhibited by N-methyl-hydantoic acid and 1-carboxymethyl-2-iminoimidazolidine-4-one, the control cells appeared to be unhealthy. (As noted above, the colon cell lines are difficult to maintain in tissue culture due to the sensitivity of the cells and possible acidification of the medium.) The asterisked values in Table 5 should be interpreted with caution, because the counts per minute of ^{3}H-thymidine incorporated in the control samples were quite low, these values may not be significant.

TABLE 4

GUANIDINO COMPOUNDS (CREATINE AND ANALOGUES)
DEMONSTRATING LITTLE OR NO EFFECT ON TUMOR
GROWTH UNDER CONDITIONS USED

Structure	Compound Name	Reference
	β-guanidino-propionic acid [1]	G6878
	N-methyl amidino-N methyl glycine [2]	Rowley, G. L. et al.; J. Am. Chem. Soc. 93: 5542-5551 (1971)
	N-ethyl-N-amidino glycine (N-ethyl guanidino acetate) [2]	Richmond,J.J. & Walker.J Aic. Biochem. Biophys. 252: 564-570 (1982)
	N-acetimidoyl-sarcosine [2]	Wang, T., J. Org. Chem. 39: 3591-3594 (1974)
	N-propyl-N-amidino glycine (N-propyl-guanidino acetate) [2]	Rowley, G. L. et al.; J. Am. Chem. Soc. 93: 5542-5551 (1971)

SUBSTITUTE SHEET

Rowley, G. L. et al., J. Am. Chem. Soc., 93: 5542-5551 (1971)

F820-03

Ann Gae Khue Nguyen, Ph.D. Thesis in Pharmaceutical Chem., UCSF (1983)

N-methyl-N-amidino-amino methyl phosphonate [2]

Creatinine [3]

1-carboxymethyl 2-iminoimidazolidine 4-one [2]

2 methyl-N-carboxy-methyl imidazole [2]

N-methyl-hydantoic acid [2]

[1] Sigma
[2] Dalton
[3] Baker

TABLE 5

Effect of Drug on Incorporation of ^{3}H-Thymidine
(% of Untreated Control)

| Amira # | 209 | 210 | 211 | 213 | 260 | 274 | 259 | 261 | 262 | 276 |
| Exp # | 42 | 42 | 42 | 42 | 81 | 81 | 75 | 75 | 75 | 84 |
Compound	A	B	C	D	E	F	G	H	I	J
Cell Line										
293	78	91	85	77	97	166	185	115	223	209
Vero	75	83	166	77	74	117(2mg/mL)	80	88	73	125
Balb-c 3T3	106	115	130	120						
C-33A	105	111	106	96	45	66	126	116	133	27
CaSki	102	106	108	76			88	97	89	
SiHa	95	91	108	91						
HeLa	107	128	112	169	121	168	130	148	107	94
DU 145	116	111	128	77			95	80	86	
PC3	111	100	119	69						
LnCAP	71	76	77	36						
SAOS-2	98	90	80	68						
U2OS	100	101	142	112			120	150	50	
SW116	141	0	158	0			172*	199*	99*	
SW48	128	0	131	0						
SW403							113	91	180*	
MRC5	103	53	37	34						
H69	92	82	98	87						

Key:
A = 2-methyl-N-carboxymethylimidazole
B = 1-carboxymethyl-2-iminoimidazolidine-4-one
C = Beta-guanidinopropionic acid
D = N-methyl-hydantoic acid
E = N-methylamidino-N-methylglycine
F = N-methyl amidino amino methyl phosphonate
G = N-methyl-N-amidinoglycine
H = N-ethyl-N-amidinoglycine
I = N-acetimidoylsarcosine
J = N-propyl-N-amidinoglycine
creatinine

SUBSTITUTE SHEET

Example 4

Inhibition of Colony Formation of Established Tumor Cell Lines in Soft Agar by Inhibitors of Creatine Kinase

The human tumor colony assay (or stem cell assay) is an in vitro culture system that differs from the DNA synthesis assay by the use of a semisolid medium support. Only transformed cells capable of self-renewal grow in this support system. Chemosensitivity testing of specific agents in the colony assay has revealed a definite heterogeneity in drug sensitivity of different tumors, and clinical correlations have now been made between chemosensitivity to an agent in this assay and the response of patients to the corresponding agent in chemotherapy. In light of the predictive value of this assay, the effect of inhibitors of creatine kinase on the ability of transformed cells to form colonies in soft agar was tested.

Tumor Cells

Human tumor cells were derived from established lines of tumor cells. Cells were purchased from the American Type Culture Collection (ATCC), Rockville, MD, except for the A2058 cell line, which was received from the Dr. M. Beckner, U.S. National Cancer Institute. Since purchase, cells have been passaged twice weekly at a subcultivation ratio of 1:6 or 1:8. Passage of adherent cells entailed

SUBSTITUTE SHEET

removal of growth medium, incubation of monolayers in 3 mls of 0.25% trypsin (J.R.H. Biosciences) for several minutes until cells detached, followed by addition of 20 mls of fresh growth medium to inactivate the trypsin.

For soft agar colony assays, cells were collected from 75 cm^2 flasks by dissociation in 5 mls of 0.25% trypsin (J.R.H. Biosciences). Trypsin was inactivated with 10 mls of EMEM + 10% FBS. Cells were pelleted in a Beckman table top centrifuge for 5 mins at 1500 rpms. The supernatant medium was removed by aspiration and the pellet was resuspended in 1-5 mls of IMDM Enriched Media (see below). Cells harvested by trypsinization were counted in a hemocytometer to determine the number of viable cells. From this stock, generally from 1.5×10^3 to 7.5×10^3 cells were added to each 35 mm dish.

Media for Cell Line Maintenance

For growth of stock tumor cell lines ME-180 (ATCC HTB 33), DU 145 (ATCC HTB 81), SK-N-MC (ATCC HTB 10; (SKNMC)), and U-87 MG (ATCC HTB 14) cells, medium consisted of 90% Minimum Essential Medium (Eagle's with Earle's Balanced Salts, without L-glutamine, J.R.H. Biosciences 51-412, EMEM), 10% fetal bovine serum, 100 U/ml Pen/Strep, 2 mM L-glutamine, 1 mM Na pyruvate. (J.R.H. Biosciences). Cells were grown in 75 cm^2 flasks at 5% CO_2, 37°C.

For SW48 (ATCC CCL 231) cells, growth medium
consisted of 90% L-15 (Leibovitz) Medium (with
L-glutamine, J.R.H. Biosciences 51-201), 10% fetal
bovine serum, 100 U/ml Pen/Strep, plus 2 mM
L-glutamine, 1 mM Na pyruvate. Cells were grown in
closed 75 cm^2 flasks at 37°C.

For CaSki (ATCC CRL 1550) and NCI-H69 (ATCC HTB
119; (H69)) cell lines, medium consisted of 90% RPMI
1640 Medium (without L-glutamine, JRH Biosciences
51-502), 10% fetal bovine serum, 100 U/ml Pen/Strep,
plus 2 mM L-glutamine, 1 mM Na pyruvate (J.R.H.).
Cells were grown in 75 cm^2 flasks at 5% CO_2, 37°C.

For NIH:OVCAR (ATCC HTB 161, (OVCAR)) colon
adenocarcinoma cells, medium consisted of 90% RPMI
1640 Medium (without L-glutamine, JRH Biosciences
51-502), 10% fetal bovine serum, 100 U/ml Pen/Strep,
plus 2 mM L-glutamine, 1 mM Na pyruvate (J.R.H.), 10
ug/ml insulin (Sigma). Cells were grown in 75 cm^2
flasks at 5% CO_2, 37°C.

For A2058 human metastatic melanoma cells,
medium consisted of 90% Dulbecco's Modified Eagle's
Medium (with 4500 mg/L Glucose, without L-glutamine,
J.R.H. Biosciences 51-432), 10% fetal bovine serum,
100 U/ml Pen/Strep, plus 2 mM L-glutamine, 1 mM Na
pyruvate (J.R.H.). Cells were grown in 75 cm^2
flasks at 5% CO_2, 37°C.

Medium for Colony Assays

For the colony assays, all cells were incubated
in IMDM Enriched Medium, which consisted of 77%
Iscove's Modified Dulbecco's Medium (IMDM), 2 mM

L-glutamine, 4 mM $CaCl_2$, 2300 mg/l $NaCl_2$, 3 U/ml insulin, 0.5 mg/ml DEAE Dextran, 1.5% BSA (Sigma A-9418), 10% FBS (Fetal Bovine Serum), 10% HS (Horse Serum), 2 mM Na Pyruvate, 100 U/ml Pen/Strep. To prepare IMDM Enriched Medium all ingredients except BSA were mixed in a 1000 ml beaker with a stir bar. BSA was then added to the mixture and allowed to dissolve for several hours. The medium was then filtered with a 0.2 μm filter and was divided into 250 ml aliquots and stored frozen at -20°C.

Preparation of Drug Stocks and Treatment Protocols

For each experiment, a freshly prepared stock concentration of 16 mg/ml cyclocreatine was made in IMDM Enriched Media. For measuring the clonogenicity of cells during continuous exposure to drug, an aliquot of the stock solution of cyclocreatine was added to the cells and agar immediately before plating to achieve a final concentration of cyclocreatine between 0 and 8.0 mg/ml. In general, there were six doses of drug per experiment and each dose was performed in quadruplicate: four 35 mm dishes for each drug concentration, including the vehicle-treated control.

For measuring the clonogenicity of cells after a limited exposure to drug, the cells were pretreated with drug for 48 hours before being plated in soft agar without drug: 1 X 10^5 cells were plated per 25 cm^2 flask and were allowed to adhere (at least 6 hours). The growth media was then

SUBSTITUTE SHEET

aspirated and replaced with 5 mls of media containing cyclocreatine at 0, 0.5, 1.0, 2.0, 4.0 or 8.0 mg/ml. Typically there were two 25 cm^2 flasks per drug concentration. The cells were exposed to the drug for 48 hours and then were removed from the flask with 2 mls of 0.25% trypsin. To remove residue of the drug, the 2 ml cell suspension was added to a centrifuge tube containing 5 ml of IMDM Enriched Medium and was centrifuged for 5 min at 1500 rpm. The cell pellet was resuspended in fresh IMDM Enriched media. The cells were then counted and added to agar without drug. The same number of viable cells were plated from each drug dose. In these cases, colony formation is assayed in the absence of drug. This assay measures the ability of the cells remaining viable after the limited exposure to drug to form colonies. The number of colonies formed does not reflect the loss of cells during the limited exposure to the drug.

Plating in Soft Agar

The soft agar used in the assays consisted of two layers: a base feeder layer of 0.5% agar and medium and a less solid top layer (0.3% agar), which holds the tumor cells. To form the base layer, approximately 1.5 mls of 0.5% Bacto Agar containing medium and serum was pipetted into 35 mm dishes and allowed to solidify at room temperature for 5 min: a 2% Bacto Agar (Difco) Solution in 1X PBS (JRH Biosciences) was sterilized by autoclaving and was stored at 4°C when not in use. Solidified agar

SUBSTITUTE SHEET

stored at 4°C was first boiled until liquid (about 5 minutes) and was then cooled to 42°C. An aliquot was checked for proper temperature with a thermometer. Three 35 mm petri dishes were placed inside a 100 mm petri dish. One of the plates was placed into the larger plate and was filled with water as needed in order to prevent dehydration of the agar in the course of the experiment. Two of the plates had lids, and were used for addition of the agar, cells and drug. From the 2% Bacto Agar solution, a second solution of 0.5% Bacto Agar was prepared using pre-warmed (37°C) 80% IMDM, 20% fetal bovine serum, 100 U/ml Pen/Strep, 2 mM L-glutamine, 1 mM Na pyruvate as the diluent.

The <u>top layer</u>, consisting of agar, medium, serum, cells and, in some cases, drug, was prepared in a 15 ml tube. Drug (0 to 1.8 ml) and cells (10 μl to 0.3 ml) were mixed with IMDM Enriched Media (an amount necessary to bring volume to 2.5 ml) followed by the addition of 0.5 mls of 2% Bacto Agar kept at 42°C (final agar concentration = 0.3%; total volume = 3 mls). This cocktail was then mixed with a 5 ml pipette. Approximately 1.2 mls of this mixture was pipetted into each of two 35 mm dishes containing a solidified layer of 0.5% Bacto Agar placed within the larger 100 mm plate. For each treatment group this process was repeated, until there were a total of four 35 mm dishes per treatment group. Approximately 3 mls of sterile water was placed in the remaining, open 35 mm petri dish within the 100 mm plate. These plates were

left at room temperature for about 5 minutes to
allow the agar to set and were then incubated at
37°C, 5% CO_2 for 3 weeks.

After 21 days, generally, the colonies were
stained with a vital stain to determine viability
and to aid visualization. 0.5 mls (0.5 mg/ml in
water) of the P-iodonitrotetralium violet (Sigma)
was added dropwise over the agar. The dye is an
electron acceptor of multiple cellular
dehydrogenases. After addition of the dye, the
plates were returned to the incubator at 37°C, 5%
CO_2 for 24 hrs. Viable cells were stained a
bluish-purple color. Stained colonies consisting of
greater than 50 cells were identified at 40X
magnification with a phase contrast microscope.

Effect of Continuous Exposure to Cyclocreatine

The in vitro chemosensitivity of tumor cells to
continuous exposure to cyclocreatine was measured
using the double-layer soft agar assay described
above. Single cell suspensions (1.5 x 10^3 to 7.5 x
10^3 cells per 35 mm dish) from different established
human tumor cell lines were plated separately in
soft agar, typically in the presence of one of at
least six different concentrations of cyclocreatine
(between 0.25 and 8.0 mg/ml). Untreated control
cells were plated with vehicle only. Each treatment
and control group was performed in quadruplicate
(four 35 mm dishes per group). After 21 to 37 days,
colonies that had formed were counted under 40X
magnification with a phase contrast microscope. (In

SUBSTITUTE SHEET

many cases the colonies were stained with a vital stain to facilitate counting.) The number of colonies formed in the untreated control groups were between approximately 50 to 750 colonies. (Experiments with less than an average of 48 colonies per control plate are not included.) The mean number of colonies formed in each treatment and control group was plotted to determine the dose required to inhibit plating efficiency by 50%.

The plating efficiency of H69 (small cell lung carcinoma), ME-180 (cervical carcinoma), SKNMC (neuroblastoma metastasis), and SW48 (colon adenocarcinoma) cells was severely reduced by continuous exposure to high doses of cyclocreatine. Clonal growth of each of these cell types was inhibited to 50% of control values by continuous exposure to approximately 0.5 mg/ml (3.5 mM) cyclocreatine. The inhibitory effect of cyclocreatine on the clonogenicity of these cells is tabulated below and is shown in each instance to be dose-related. That is, the higher the drug dose, the fewer number of colonies were formed. For H69 cells, at continuous exposure to 2 mg/ml cyclocreatine, no colonies of greater than 50 cells had formed within 23 days. For ME-180 cells, clonal growth was inhibited by 99% at 2 mg/ml cyclocreatine. For SKNMC cells, clonogenicity was reduced by 98% at 2.0 mg/ml cyclocreatine as compared with the untreated control. Growth of SW48 cells was reduced by 95% at 1.0 mg/ml cyclocreatine

SUBSTITUTE SHEET

as compared with the untreated control. No colonies
of the minimum size formed at either 1.5 mg/ml or
2.0 mg/ml cyclocreatine.

Table 6

Ccr (mg/mL)	Average Number of Colonies Formed			
(Cell Line)	H69	ME-180	SKNMC	SW48
0.0	45	110	113	334
0.25	n.d.*	n.d.	n.d.	252
0.5	28	39	75	157
0.75	n.d.	n.d.	n.d.	41
1.0	12	17	28	18
1.5	6	3.5	n.d.	0
2.0	0	1	2	0
2.5	0	1	n.d.	n.d.
3.0	0	1	n.d.	n.d.
4.0	0	0	0	n.d.
8.0	0	0	0	n.d.

* n.d. indicates not done.

The plating efficiency of OVCAR cells was
reduced significantly, although not as severely as
for the cell lines shown in Table 6. The CD50 for
OVCAR cells was 0.8 mg/ml. However, the CD50 may be
somewhat overestimated for this cell line, because
the average number of colonies in the control plates
exceeded 1000, making an accurate count difficult.

SUBSTITUTE SHEET

At 2.0 mg/ml, 4.0 mg/ml, and 8.0 mg/ml cyclocreative, clonal growth of OVCAR cells was reduced by 89%, 93%, and 95%, respectively, as compared with the untreated control.

The plating efficiency of U-87 MG (gliobastoma, astrocytoma) cells was reduced by 50% at a 10X higher dose than that of ME-180 cells: 5.5 mg/ml (39 mM). At 4.0 mg/ml, colonies were reduced by 31%, and at 8.0 mg/ml, colonies were reduced by 80%, relative to the untreated control.

Under the conditions of the assay, the growth of A2058 cells was unaffected by the highest concentration of cyclocreatine tested, which was 8.0 mg/ml or 56 mM cyclocreatine.

<u>Effect of 48 Hour Exposure of Cells to Cyclocreatine</u>

The in vitro chemosensitivity of tumor cells to a 48 hour exposure to cyclocreatine was also measured using the double-layer soft agar assay. 1×10^5 cells from several different cell lines were plated in 25 cm^2 flasks and treated for 48 hours with selected concentrations of cyclocreatine in duplicate before being plated in soft agar <u>in the absence of drug</u>. Untreated control cells were incubated for an equivalent time with vehicle only. Single cell suspensions (1.5×10^3 to 7.5×10^3 cells per 35 mm dish) from each flask were plated in the absence of drug in two 35 mm dishes. Each treatment and control group was thus performed in quadruplicate (two 25 cm^2 flasks into four 35 mm dishes per group). After 21 to 37 days, colonies

SUBSTITUTE SHEET

that had formed were counted under 40X power with a
phase constrast microscope. In many cases the
colonies were stained with a vital stain to
facilitate counting. Approximately 50 to 750
colonies were formed in the untreated control
groups. (Experiments with less than an average of 48
colonies per control plate are not included.) The
mean number of colonies formed in each treatment and
control group was plotted to determine the dose
required to inhibit plating efficiency by 50%
(CD50).

The CD50 values for 48 hour exposure to
cyclocreatine for each of the five cell lines tested
is tabulated below (Table 7).

Table 7

Cell Line	CD50 (48 hour exposure) Cyclocreatine (mg/ml)
OVCAR*	0.6
H69	1.0
ME-180	1.8
DU-145	2.6
A2058	> 8.0

*Only three doses: 0.5, 1.0 and 2.0 mg/ml

Except for the A2058 cells, which were
unaffected by cyclocreatine, all cells tested
exhibited a dose response to cyclocreatine. As the

SUBSTITUTE SHEET

concentration of drug was increased, fewer cells achieved the minimum colony size in the time allowed.

The results of these experiments, together with the results obtained for continuous exposure to drug (see above), indicate that cyclocreatine inhibits the clonal growth of a variety of representative tumor cell lines. Furthermore, it is interesting to note that the cell lines most reproducibly inhibited by drug treatment as assayed by colony formation are those with the highest creatine kinase levels: H69 and ME-180 (Tables 1, 6 and 7). A2058, on the other hand, which expresses no detectable creatine kinase (data not shown), is unaffected by cyclocreatine. On the basis of the proven predictive value of soft agar colony assays, and the activity of cyclocreatine in this assay, it is concluded that cyclocreatine is an effective anti-tumor agent. These observations further suggest that tumors chemosensitive to cyclocreatine can be identified by screening biopsy samples for elevated creatine kinase activity, as compared with normal tissues.

Example 5

Inhibition of Colony Formation of Fresh Human Biopsy Tumor Samples in Soft Agar by Inhibitors of Creatine Kinase

Cells

Malignant ascites containing tumor cells were collected as part of a diagnostic workup or

SUBSTITUTE SHEET

treatment of disease. Effusions were collected in preservative-free heparinized vacuum bottles, centrifuged at 150 X g for 10 minutes, and washed twice in Hank's balanced salt solution with 10 percent heat-inactivated fetal calf serum and 1% penicillin and streptomycin solutions. Viability of the cells was determined by trypan blue exclusion.

Drug Testing

Cyclocreatine and homocylcocreatine were added to 15 ml conical tubes. (The amount of drug added was determined by the volume of the drug stock added.) 2.0 ml of double-enriched Connaught Medical Research Laboratories (CMRL) medium was then added per tube. Finally, 0.5 ml of cells were added to each tube. Controls containing the corresponding solvent for each drug (i.e., water) were also tested. Tubes were vortexed and the contents were plated. 0.3 ml agar (measured in a 5 ml pipette) was drawn into the prepared 15 ml conical tube and mixed twice. The mixture was then drawn up and 1 ml was added to each plate. Plates were incubated at 37°C in 5-7% CO_2 and 100% humidity for a period of 14 days.

Media

ENRICHED CMRL 1066

For 500 mls of medium, to 400 ml CMRL 1066 (GIBCO #321-1535AJ) was added 75 ml Horse Serum (Hyclone), 10 ml Fetal Calf Serum (Hyclone), 10 ml

SUBSTITUTE SHEET

Insulin (100 Units/ml), 5 ml Vitamin C (30 mM), 5 ml penicillin/streptomycin (5,000 U/ml, Baxter Cat. #T3512-30).

DOUBLE ENRICHED CMRL 1066

To 100 ml Enriched CMRL was added 1.5 ml asparagine (6.6 mg/ml) and 2.0 ml glutamine (200 mM). The pH was adjusted with 1 N HCl to give a final pH of 7.0 - 7.2 (~0.3 ml 1N HCl per 100 mls).

Plate Preparation

The underlayer was composed of 1 ml of 0.42% agar in plating medium. 2.5% Difco agar was diluted to 0.42% agar with the plating medium (40 ml Enriched McCoy's, 10 ml tryptic soy broth (3% in distilled H_2O), 0.6 ml asparagine (6.6 mg/ml), 0.3 ml DEAE dextran (50 mg/ml), 0.4 ml glutamine (200 mM)). Ingredients were combined immediately before use: 10 ml of plating medium plus 2 ml 2.5% agar = 1/6 concentration (0.42%). This was mixed twice and 1 ml aliquots were added to twelve 35 mm petri dishes.

The top layer consisted of 1 ml of 0.25 agar. 2.5% agar was diluted to 0.25% agar with double Enriched CMRL 1066. 0.3 ml of 2.5% agar at 45 -50°C was added to each tube containing media, cells, and either drug or control solvent. The 0.3 ml agar was added with a 5 ml pipette. The resulting

SUBSTITUTE SHEET

approximaty 3 ml's was mixed twice and then drawn up
and 1 ml was added to each plate.

Effect of Cyclocreatine and Homocyclocreatine on
Colony Formation of Freshly Collected Ovarian
Ascites Cells

Ovarian Ascites tumor specimens were collected
from a patient with ovarian cancer, were transferred
to tubes in the presence of the appropriate drug
dilution or control medium and were cultured in
triplicate as described above. The number of
colonies formed in the presence of 0.2, 2.0 and
20.0 mM homocyclocreatine (Table 8) and in the
presence of 0, 0.067, 0.670 and 6.700 mM
cyclocreatine (Table 9) are tabulated below.

SUBSTITUTE SHEET

TABLE 8

HOMOCYCLOCREATINE INHIBITS THE GROWTH OF FRESH HUMAN TUMOR CELLS

(OVARIAN ASCITES CELLS) IN CLONOGENICITY ASSAYS

COMPOUND	DRUG CONC.	DISH 1	DISH 2	DISH 3	AVG	CONTROL	% RED
			(# of colonies)				
Homocyclo-creatine	0.2 mM	14	20	15	16	22	26%
"	2.0 mM	17	15	12	15	22	33%
"	20.0 mM	8	9	7	8	22	64%

TABLE 9

CYCLOCREATINE INHIBITS THE GROWTH OF FRESH HUMAN TUMOR CELLS

(OVARIAN ASCITES CELLS) IN CLONOGENICITY ASSAYS

COMPOUND	DRUG CONC.	DISH 1	DISH 2	DISH 3 (# of colonies)	AVG	CONTROL	% RED
Cyclocreatine	0.067 mM	19	20	22	20	22	8%
"	0.670 mM	19	13	18	17	22	24%
"	6.700 mM	16	13	11	13	22	39%

Treatment with 20 mM homocyclocreatine and 6.7 mM cyclocreatine reduced the number of colonies formed significantly. The two compounds showed less consistent growth inhibition of two additional biopsies. Nevertheless, these experiments with freshly derived tumor specimens confirm the antiproliferative effects of cyclocreatine observed above against established cell lines, indicating that the anti-proliferative activity of these compounds is not due to an anomolous property of the established cell lines. In addition, it is noted that the creatine kinase activity of these biopsies is unknown; therefore, the samples may not represent the most drug sensitive tumor types.

Example 6

A Creatine Kinase Inhibitor, Cyclocreatine, Reduces the Growth of Human Tumor Xenografts in Nude Mice

In previous studies investigating the ability of creatine kinase inhibitors to sustain ATP levels or delay rigor during ischemic eposides in muscle, cyclocreatine and other creatine analogs have been fed to mice, rats and chicks. All analogs were well-tolerated. Griffiths and Walker reported that chicks fed a diet containing 1 % cyclocreatine rapidly accumulated cyclocreatine-phosphate in breast muscle, a tissue rich in creatine kinase activity. Cyclocreatine also accumulated in heart and brain, although to a lesser extent. Chicks

tolerated 1% cyclocreatine in the diet if an
antibiotic (oxytetracycline) was also ingested,
although these chicks grew more slowly than control
chicks. Griffiths and Walker also reported that
cyclocreatine was taken up by muscle, heart and
brains in rats fed a diet containing 1%
cyclocreatine (Griffiths, G.R. and J. B. Walker, _J._
Biol. Chem., _251_: 2049-2054 (1976)).

Because cyclocreatine displayed reproducible
antitumor activity in vitro (described above), was
acceptably pure and was well-tolerated by animals,
several experiments were performed to test whether
cyclocreatine could inhibit the growth of human
tumor xenografts in nude mice. Tumor cells selected
on the basis of their in vitro sensitivity were
implanted into mice by injection of cells grown in
tissue culture or transplantation of tumor fragments
grown in nude mice. After injection or implantation
of cells or after formation of a palpable tumor,
dietary (0.25 - 1.0%) drug was administered by
mixture with chow. These amounts of cyclocreatine
have been shown to accumulate in different organs in
animals in mM concentrations; millimolar
concentrations have been shown herein to have
anti-proliferative activity in vitro. Tumor growth
in the presence or absence of drug was followed by
outside measurement of the growing tumor with ruler
or caliper or by actual measurement of necropsied
tumor.

SUBSTITUTE SHEET

<u>Cyclocreatine reduces the growth of newly
established tumors derived from a human epidermoid
carcinoma cell line in nude mice</u>

<u>Cells</u>

ME-180 cells are derived from a metastasis to
omentum of a human epidermoid carcinoma of the
cervix (<u>J. Nat. Cancer Inst.</u> <u>45</u>: 107-122, (1970)).
Cells were purchased from the ATCC. The cells were
passaged twice weekly for nine months before
injection at a subcultivation ratio of 1:6, 1:8 by
trypsinization. Medium consisted of 90% Minimum
Essential Medium (Eagle's with Earle's Balanced
Salts, without L-glutamine, J.R.H. Biosciences
51-412, EMEM), 10% fetal bovine serum, 100 U/ml,
Pennicillin/Streptomycin, 2 mM L-glutamine, 1 mM Na
pyruvate (J.R.H. Biosciences). Cells were grown in
75 cm^2 flasks at 5% CO_2, 37°C.

To harvest sufficient cells for the experiment,
eight 225 cm^2 and ten 150 cm^2 confluent flasks of
ME-180 cells were treated with 5 mls of 0.25%
trypsin until the cells detached from the flask.
Trypsin was inactivated with 10 mls of McCoy's
medium + 10% FBS. Cells were collected by
centrifugation for 5 mins at 1500 rpm. The
supernatant was removed by aspiration and the pellet
was resuspended in 40 ml of plain (no serum) media.
The cell suspension was centrifuged again and the
pellet was resuspended in 5 mls of serum free
McCoy's media. A cell count was performed to
determine cell number and viability. 3.8×10^7

SUBSTITUTE SHEET

cells were injected subcutaneously into one hind
limb of each mouse. Injections were performed with
a 1 cc syringe and a 26 G needle.

Tumors were measured from the exterior with a
ruler held horizontally to the body of the mouse to
determine the width, and perpendicularly to
determine the height of the tumor. In some cases
two tumors were visible. Tumor volume was estimated
as the product of the width and the length squared
divided by 2.

Mice

Nude (athymic) male mice from Charles River
Breeding Labs were delivered as 8-10 week old mice.
These mice were housed at the University of
Massachusetts Animal Medicine Facility. Mice were
acclimated for nineteen days before injection. To
identify each mouse, a small hole was punched at a
specific position of the outermost part of the right
or left ear. The average weight of the mice at the
beginning of the experiment was 28 grams.

Animal Husbandry Techniques

Mice were housed at the II Biotech Park Animal
facility operated by the University of Massachusetts
Medical Center, 55 Lake Avenue North, Worcester, MA.
The animal room is kept at a temperature of 72°F,
relative humidity of 40-70%. The animals are housed
in polycarbonate mouse cages (Lab Products
microisolator units, Lab Products, Inc., Maywood,
NJ). Animals are housed on autoclaved bedding

(Sani-Chip; P.J. Murphy, Inc., Montville, NJ).
Animals are fed ad libitum Purina Diet 5010
autoclavable, (Purina, Inc.) and sterilized water.
Animals are manipulated for husbandry under a
laminar flow workstation (Nuaire, Inc.). Animal
cages are changed weekly.

Preparation of Drug

After injection of tumor cells, the mice were
fed sterile ground meal from Farmers Exchange #5010
Picolab Mouse Chow. Meal was placed in jars holding
100 grams of chow, which were replaced twice weekly.
Cyclocreatine (Ccr) was ground into the meal using
the plunger section of a 60 cc syringe to reach a
final concentration of 0.25%, 0.5%, 0.75%, or 1.0%
cyclocreatine. This mix was added to sterile jars
and placed in the cages and the standard pellet was
removed.

Results

ME-180 cell-derived tumors were initiated in 25
nude mice by injection of 3.8×10^7 cells per mouse
subcutaneously in one hind limb of each mouse. Mice
were returned to their original cages (5 mice per
cage). 5 days after injection, tumors were palpable
in each of the injected animals. On day 5, the test
drug cyclocreatine was added as a supplement to the
diet at 0.0 %, 0.25 %, 0.5 %, 0.75 %, and 1.0 %
concentrations, with one selected concentration per
cage. Mice were allowed to eat the mixture of drug

and meal ad libitum. Tumor sizes and animal weights were recorded for the next two weeks.

Mice fed 0% cyclocreatine for two weeks gained on average 2 g ± 1.4 g, while mice fed 1 % cyclocreatine in the diet did not gain weight on average. No concentration tested induced a weight loss, on average. In several other experiments, different strains of nude mice and normal mice were observed to gain weight when fed 1% dietary cyclocreatine.

Addition of cyclocreatine to the diet of mice with preformed, palpable tumors inhibited tumor growth in a dose related manner. Tumors in mice fed 0% cyclocreatine grew on average 19 mm^3 from week one to week three. Tumors in mice fed 0.25% cyclocreatine grew on average 20 mm^3. Tumors in mice fed 0.5% cyclocreatine grew only 11 mm^3. Tumors in mice fed 0.75% and 1.0% cyclocreatine did not grow and may have regressed (mean change in volume of -1 and -6 mm^3, respectively). It is concluded that cyclocreatine behaved as an effective antitumor drug in this experiment with no obvious toxicity (apart from a slight reduction of weight gain).

Cyclocreatine reduces the growth of ME-180 derived tumors in nude mice at the two week time point

Tumors were initiated by transplantation of tumor fragments derived from ME-180 cells injected into nude mice. 1 X 10^6 ME-180 cells were injected subcutaneously at the dorsal midline near the neck

SUBSTITUTE SHEET

of 2 nude CD-1 mice. The tumors were excised after 4 weeks of growth and were cut into approximately 1-2 mm^3 fragments with a scalpel blade, under sterile conditions. Mice were anesthetized and a 3 mm incision was made at the dorsal midline of each animal. A tumor fragment judged viable by the absence of color was placed into the incision with sterile forceps. The wound was closed with a wound clip, which was removed two weeks later. 30 CD-1 nude mice were inoculated with fragments of an ME-180-cell-derived tumor.

Mice

Nude (athymic) CD-1 male mice from Charles River Breeding Labs were delivered at 5 weeks of age.

Results

ME-180-derived tumors were initiated in 30 nude mice by transplantation of tumor fragments. After transplantation, mice were grouped 5 to a cage. The animals were started on a continuous drug regimen the same day. Two cages of control mice received 0% cyclocreatine, two cages of mice received 0.5% cyclocreatine chow, and two cages of mice received 1.0% cyclocreatine chow. After two weeks, five mice from each group were sacrificed. The remaining mice were sacrificed at week three. The mean volume of excised tumors for the control group was 19.7 mm^3 (± 19.2 mm^3). For animals receiving 0.5% drug, the average volume of the tumors reached 8.88 mm^3 (±

SUBSTITUTE SHEET

6.3 mm^3), and for those receiving 1.0%, the average
tumor volume was only 4.07 mm^3 (± 1.5 mm^3). One
tumor in the control group did not form, introducing
a large standard error in the measurement for the
control group. Although the large variation in
average tumor volume in the control group minimizes
the statistical significance of this experiment,
there is a clear dose response at this time point.
The mice sacrificed at the three week time point
showed no clear drug effect, with tumor volumes
averaging 14.9 mm^3 (± 19.4 mm^3), 24.8 mm^3 (± 19.6
mm^3), and 11.5 mm^3 (± 9.1 mm^3) from 0.0%, 0.5%, and
1.0% cyclocreatine-fed animals, respectively.

Control animals grew modestly over the two to
three week period of the experiment. The controls
sacrificed at the two week time point had an average
weight gain of 1.9 g (increasing from an average of
28.8 g to 30.7 g) at the time of sacrifice, while
the group sacrificed after three weeks had grown on
average 0.8 g (increasing from an average of 29.4 g
to 30.2 g) at the time of sacrifice. Animals fed
0.5% cyclocreatine behaved similarly. Animals fed
1% cyclocreatine in their diet showed no significant
weight gain or loss in either group.

The antitumor effect of 1% cyclocreatine on the
growth of tumors at the two week time point is
consistent with the antitumor activity observed in
the previous experiment. The lack of effect
observed at the three week time point may be due to
the stepwise growth of tumors in this model. While
the tumors in the control group may have reached a

SUBSTITUTE SHEET

plateau after two weeks, the tumors in animals
treated with 1% cyclocreatine may have caught up.

Cyclocreatine reduces the growth of human colon adenocarcinoma cells in nude mice

Cells

SW48 cells are human colon adenocarcinoma cells
(Leibovitz et al., Cancer Res. 36: 4562-4569
(1976)). SW48 cells were purchased from the ATCC
and are described further in Materials and Methods
above. The cells were passaged twice weekly for
nine months before injection at a subcultivation
ratio of 1:3, 1:5. Feeding of cells was carried out
as follows: media was removed by aspiration, 3 mls
of fresh 0.25% Trypsin were added, plates were
incubated for 1 minute until the cells were
detached, and cells were added to 20 mls of fresh
medium. Medium consisted of L15 Leibovitz, 90%;
Fetal bovine Serum, 10%; Penicillin/Streptomycin,
1%; glutamine, 1%; Na pyruvate, 1%. Cells were
incubated at 5% CO_2, 37 °C.

Mice

Nude (athymic) CD-1 male mice from Charles
River Breeding Labs were delivered at 5 wks of age.
Mice were acclimated for 3 weeks before fragment
insertion. Mice were identified during the course
of the experiment for multiple measures of tumor
size and mouse weight by the placement of a small
hole punch in one ear. The average weight of the

SUBSTITUTE SHEET

mice at the beginning of the experiment was 29 grams.

Tumor Measurement and Calculation

All tumors were initiated by transplantation of tumor fragment derived from SW48 cells injected into nude mice. 1×10^6 SW48 cells were injected subcutaneously at the dorsal midline near the neck of 2 nude CD-1 mice. The tumors were excised after 4 weeks of growth and were cut into 1-2 mm^3 fragments with a scalpel blade, under sterile conditions. Mice were anesthetized and a 3mm incision was made at the dorsal midline. A tumor fragment judged viable by the absence of color was placed into the incision with sterile forceps. The wound was closed with a wound clip that was removed two weeks later. 45 CD-1 nude mice were inoculated with fragments of an SW48-cell-derived tumor.

Two days (day 3) after insertion of the tumor fragment (day 1), cyclocreatine was introduced into the diet of 6 of the 9 cages of mice. 3 cages received 0.5% cyclocreatine, and 3 received 1.0% cyclocreatine mixed with their meal. On day 14, a 2 week time point was obtained following sacrifice and necropsy of 5 mice (one cage) per treatment group and control. The measurements of actual tumor volumes after necropsy are tabulated in Table 10. There was no dose-related response or significant statistical difference among the three groups.

Table 10

Average Tumor Volumes (2 week time point, mm^3)

% cyclocreatine:	0%	0.5%	1.0%
end (2 wk time point)	6.6	10.9	5.3
	(1.7)*	(6.2)	(2.5)

_____

* Values in parentheses are standard deviations of the measured values.

Beginning on day 19, outside tumor measurements were tracked for the remaining 6 cages of mice, 2 cages per treatment and control group. On day 45, the experiment was terminated and the actual tumor volumes were calculated upon necropsy. The average tumor volumes determined for each of the days are listed below in Table 11 and values for days 19-30 post-drug addition are illustrated graphically in Figure 12. In Figure 12, the mean tumor volume (mm^3) is plotted against the time (days post-drug addition) for each treatment group.

SUBSTITUTE SHEET

Table 11

Average Tumor Volumes (time course, mm^3)

% cyclocreatine:	0.0%	0.5%	1.0%
day 19	92.1 (84)*	132.6 (87.7)	33.5 (18.6)
day 23	123.5 (92.7)	125.4 (77.6)	38.1 (28.6)
day 26	168.8 (119)	196.0 (143)	49.7 (35.1)
day 30	278.8 (267.1)	332.6 (252.9)	66.3 (59.7)
day 34	424.6 (335.2)	398.9 (301)	101.8 (89.8)
day 37	521.8 (459)	487.8 (426.1)	131.5 (128.4)
day 41	478.4 (447)	710.5 (701)	169.5 (143.3)
end (day 43) (actual)	650.6 (579.8)	851.9 (950)	221.1 (176.4)

* Values in parentheses are standard deviations.

It is concluded that there is a significant reduction in growth of SW48-derived tumors in nude mice fed 1% dietary cyclocreatine ad libitum. The reduction in tumor growth is apparent in each exterior measurement from day 19 to 41 and in the actual measurement at autopsy. In contrast to the tumors initiated in the animals fed with 1% drug, the tumors in the animals fed with 0.5% drug exhibited no obvious changes in growth pattern when compared to the 0% cyclocreatine controls.

In contrast to the antitumor effect of the 1% cyclocreatine diet on tumor growth, there is no

SUBSTITUTE SHEET

obvious toxicity of the drug. There was no
significant reduction in animal weight gain in the
group treated with 1% cyclocreatine as compared with
the control (0%), although there was a modest
difference between the means.

Table 12

Average Mouse Weight (g)

% cyclocreatine:	0.0%	0.5%	1.0%
start (day 6)	28.6 (1.3)*	30.2 (1.8)	29.2 (2.4)
end (day 41)	29.9 (3.9)	31.8 (3.9)	28.4 (4.5)

* Values recorded in parentheses are standard deviations.

Cyclocreatine inhibits the growth of established (> 50 mm^3) ME-180 cell derived tumors in nude mice

Cells

ME-180 cells are human cervical epidermoid carcinoma,
derived from a metastasis to omentum, and are described
further in Materials and Methods above (J. Nat. Cancer
Inst., 45: 107-122, 1970).

Mice

Nude (athymic) male mice from Charles River Breeding
Labs were delivered at 4-5 weeks of age. Mice were
acclimated for nine days before injection.

Results

38 mice in eight cages (5 mice in each of 7 cages, and 3 mice in one cage) were each injected subcutaneously at the dorsal midline with 2×10^6 cells in 0.2 ml, using a 1 cc syringe and a 26 G meedle. Tumors were allowed to grow for 24 days after which cages of mice were selected to receive 0%, 0.5%, 0.75% or 1.0% cyclocreatine mixed in their diet as described above. 2 cages containing 5 mice each received no drug and served as controls.

Only 6 of the 10 mice in the control cages qualified for the experiment by having tumors greater than 50 mm^3 (n = 6; average tumor volume = 146.3 mm^3 ± 77 mm^3). The other 4 mice were left in the cages in order to maintain the feeding patterns of the experimental mice.

Two cages were selected to receive 0.5% cyclocreatine. Only 3 of the eight mice had tumors greater than 50 mm^3 on day 24 (n = 3; average tumor volume = 86.9 mm^3 ± 25.2 mm^3). Two cages containing 9 mice received 0.75% dietary cyclocreatine. Only 3 of these mice qualified for the experiment (n = 3; average tumor volume = 147.5 mm^3 ± 84 mm^3). Two cages totalling 10 mice were selected to receive 1% cyclocreatine. 7 of these 10 mice qualified for the experiment (n = 7; average tumor volume = 165.4 mm^3 ± 98 mm^3). Cages receiving 0% and 1% drug were chosen to maximize the number of qualifying mice and to match starting average tumor volumes as closely as possible for a meaningful comparison. Mice were fed drug for 42 days.

During the course of the experiment, several mice died, including one from the 0% group, one from the 0.75% cyclocreatine-fed group, and two from the 1%

SUBSTITUTE SHEET

cyclocreatine-fed group. (The animal in 0.75% group appeared sickly and was sacrificed before the drug regimen was started.) The deaths appeared random and were without a known cause. The tumor volumes of the remaining mice were determined and are tabulated below in Table 13.

Table 13

Average Volume of Tumor (mm^3)

% cyclocreatine:	0.0%	0.5%	0.75%	1.0%
start	146 (77)*	86.9 (25.2)	147.5 (84)	165.4 (98)
end	1224.5 (1046)	873 (905)	763.4 (951)	657.6 (603)

* Values in parentheses are standard deviations.

Table 14

Average Change in Tumor Volume (mm^3)

% cyclocreatine:	0%	0.5%	0.75%	1.0%
end	1078.2	786	615.9	492.2

As can be seen from this data, there is a dose-related reduction in tumor growth in cyclocreatine-fed animals. Tumors in animals fed 1% cyclocreatine grew 2.2 times less than tumors in control animals.

SUBSTITUTE SHEET

The volumes of the tumors that were too small at the start of the experiment to qualify (less than 50 mm^3) were also measured during the course of the experiment. In Tables 15 and 16, these volumes are included in determining the mean tumor volumes (Table 15) and mean change in tumor volume as of the end of the experiment (Table 16) for mice subjected to the various drug regimens. The average change in tumor volumes (mm^3) are also displayed in the form of a graph in Figure 13, in which the average change in tumor volume for different drug regimens is plotted against time (days post-drug administration).

Table 15

Average Volume of Tumor (mm^3)

% cyclocreatine:	0.0%	0.5%	0.75%	1.0%
start	106 (85.6)*	54.8 (30.4)	65.5 (75.4)	122.5 (100.2)
end	1033 (1049)	752.1 (605)	461.4 (620)	464.9 (531)

* Values recorded in parentheses are standard deviations.

Table 16

Average Change in Tumor Volume (mm^3)

% cyclocreatine:	0.0%	0.5%	0.75%	1.0%
end	927	697.3	395.5	342.4

SUBSTITUTE SHEET

These results mirror those calculated using only the tumors grown to a size greater than 50 mm^3 at the start of the experiment. There appears to be a dose-related reduction of tumor volume in the cyclocreatine-fed animals. It is concluded that cyclocreatine reduces the growth of both "established" and "unestablished" tumors.

The weight of each mouse was monitored during the course of the experiment. The average weights determined are shown below in Table 17.

Table 17

Average Weight of Mice

% cyclocreatine:	0.0%	0.5%	0.75%	1.0%
Start	28.9 (1.1)*	28.4 (2.3)	28.7 (1.0)	29.4 (1.0)
End	31.4 (1.3)	33.8 (3.7)	28.7 (2.1)	27.3 (3.3)

* Values recorded in parentheses are standard deviations.

A slight decrease in weight that is not statistically significant was observed in the 1% drug-fed group. No other sign of potential drug-related toxicity was observed.

It is concluded from these examples that cyclocreatine has anti-tumor activity in vivo in human tumor xenograft models. The absence of gross toxicity is consistent with in vitro results with normal cell lines and with other feeding experiments

done by Walker and colleagues in investigations of
ischemia. Cyclocreatine apparently possesses both
the potency and specificity necessary in an
effective antiproliferative, anticancer drug.

CLAIMS

1. Use of a drug capable of inhibiting purine metabolic enzyme activity, for the manufacture of a medicament for inhibiting growth or metastasis of a mammalian cell in which activity of purine metabolic enzyme (e.g. creatine kinase, adenylate cyclase, adenylate kinase, adenosine deaminase or adenosine kinase) is elevated, by e.g. a DNA tumor virus or a DNA tumor virus factor.

2. Use according to Claim 1, wherein the drug is selected from the group consisting of:
    a) cyclocreatine;
    b) homocyclocreatine;
    c) 1-carboxymethyl-2-iminohexahydro-pyrimidine;
    d) guanidinoacetate; and
    e) carbocreatine.

3. Use of a drug selected from the group consisting of:
    a) cyclocreatine;
    b) homocyclocreatine;
    c) 1-carboxymethyl-2-iminohexahydro-pyrimidine;
    d) guanidinoacetate; and
    e) carbocreatine;

SUBSTITUTE SHEET

for the manufacture of a medicament for inhibiting transformation, growth or metastasis of a mammalian cell, for example a cell in which creatine kinase activity is elevated by e.g. a DNA tumor virus or a DNA virus factor.

4. Use according to any one of Claims 1, 2 and 3 wherein the DNA tumor virus is selected from the group consisting of papovaviruses, Herpes viruses, and adenoviruses.

5. Use according to Claim 4 wherein the papovavirus is a human papillomavirus and the DNA tumor virus factor is a product encoded by the E7 gene of human papillomavirus.

6. Use according to Claim 5 wherein the human papillomavirus is selected from the group consisting of human papillomavirus 16, human papillomavirus 19, human papillomavirus 31 and human papillomavirus 33.

7. Use according to Claim 4 wherein the DNA tumor virus is an adenovirus and the DNA tumor virus factor is an adenovirus E1a gene product or an oncogenic factor induced by adenovirus.

8. Use of a drug selected from the group consisting of:
   a)   cyclocreatine;
   b)   homocyclocreatine;

c)   1-carboxymethyl-2-iminohexahydro-
        pyrimidine;

d)   guanidinoacetate; and

e)   carbocreatine;

for the manufacture of a medicament for
inhibiting transformation, growth or metastasis
of a mammalian cell, for example a cell in
which the activity of a purine metabolic enzyme
is elevated.

9.   A method of inhibiting growth or metastasis of
        a mammalian cell in which activity of a purine
        metabolic enzyme is elevated, comprising
        inhibiting activity of the purine metabolic
        enzyme by contacting the mammalian cell with a
        drug capable of inhibiting purine metabolic
        enzyme activity, under appropriate conditions.

10.   The method of Claim 9 which is a method of
        inhibiting growth or metastasis of a mammalian
        cell in which activity of a purine metabolic
        enzyme is elevated by a DNA tumor virus, a DNA
        tumor virus factor or other factor which has an
        equivalent effect on the mammalian cell.

11.   The method of Claim 9 wherein the purine meta-
        bolic enzyme is selected from the group
        consisting of: creatine kinase, adenylate
        cyclase, adenylate kinase, adenosine deaminase,
        and adenosine kinase.

SUBSTITUTE SHEET

12. The method of Claim 11 wherein the purine
    metabolic enzyme is creatine kinase and the
    drug is selected from the group consisting of:
    a)   cyclocreatine;
    b)   homocyclocreatine;
    c)   1-carboxymethyl-2-iminohexahydropyri-
          midine;
    d)   guanidinoacetate; and
    e)   carbocreatine.

13. The method of Claim 9 wherein the appropriate
    conditions are conditions appropriate for the
    drug to pass into the mammalian cell, thereby
    resulting in passage of the drug into the
    mammalian cell.

14. The method of Claim 9 wherein the appropriate
    conditions are conditions appropriate for the
    drug to remain at or within the mammalian cell
    membrane, thereby resulting in the drug's
    remaining at or within the mammalian cell
    membrane.

15. The method of Claim 10 wherein inhibiting
    activity of a purine metabolic enzyme is
    carried out by inhibiting the purine metabolic
    enzyme whose activity in the mammalian cell is
    elevated.

16. The method of Claim 15 wherein the DNA tumor
    virus is selected from the group consisting of

SUBSTITUTE SHEET

papovaviruses, Herpes viruses, and
adenoviruses.

17. The method of Claim 16 wherein the papovavirus
is a human papillomavirus and the DNA tumor
virus factor is a product encoded by the E7
gene of human papillomavirus.

18. The method of Claim 17 wherein the human papil-
lomavirus is selected from the group consisting
of human papillomavirus 16, human
papillomavirus 19, human papillomavirus 31 and
human papillomavirus 33.

19. The method of Claim 16 wherein the DNA tumor
virus is an adenovirus and the DNA tumor virus
factor is an adenovirus E1a gene product or an
oncogenic factor induced by adenovirus.

20. A method of inhibiting in a mammal the metasta-
sis of a mammalian cell in which activity of a
purine metabolic enzyme is elevated, comprising
administering to the mammal a compound capable
of inhibiting the activity of the purine meta-
bolic enzyme.

21. A method of Claim 20 wherein a DNA tumor virus,
DNA tumor virus factor or other factor has
acted to increase the activity of the purine
metabolic enzyme.

SUBSTITUTE SHEET

22. The method of Claim 21 wherein the purine metabolic enzyme is creatine kinase.

23. A method of inhibiting in a mammal the growth of a transformed cell in which the activity of a purine metabolic enzyme is elevated, comprising administering to the mammal a compound which inhibits the activity of the purine metabolic enzyme.

24. The method of Claim 23 wherein a DNA tumor virus, DNA tumor virus factor or other factor has acted to increase the activity of the purine metabolic enzyme.

25. The method of Claim 24 wherein the purine metabolic enzyme is creatine kinase.

26. A method of inhibiting growth or metastasis of a mammalian cell in which activity of a purine metabolic enzyme is elevated, comprising contacting the mammalian cell with a drug selected from the group consisting of:
    a) cyclocreatine;
    b) homocyclocreatine;
    c) 1-carboxymethyl-2-iminohexahydro-pyrimidine;
    d) guanidinoacetate; and
    e) carbocreatine.

SUBSTITUTE SHEET

27. A method of determining the sensitivity of a
     tumor, present in an individual, to
     cyclocreatine comprising determining the level
     of creatine kinase activity in a specimen of
     the tumor or serum sample obtained from the
     individual, wherein elevated creatine kinase
     activity in the specimen of the tumor or serum
     sample or a high level of creatine kinase
     activity is indicative of sensitivity to
     cyclocreatine.

SUBSTITUTE SHEET

FIG. 1

	+pBr322	+pE1a	+p858
	2.4%	98.6%	62.8%
	1.9%	55.1%	19.1%
	0.7%	21.2%	8.1%
	0.1%	1.4%	0.1%
	<0.1%	<0.1%	<0.1%

FIG. 2

FIG. 3

4/16

FIG. 4

FIG. 5A

5/16

FIG. 5B

FIG. 6A

FIG. 6B

FIG. 7

Sequence of phck111f

```
  1  CAGATCGAAA CGCTCTTCAA GTCTAAGAAC AACTACGAGT TCATGTGGAA CCCTCACCTG
 61  GGCTACATCC TCACCTGCCC CTCCAACCTG GGCACGGGGC TGCGGGCAGG CGTGCACATC
121  AAGCTGCCCC ACCTGGGCCA GCACCAGAAG TTCTCCCAGG TGCTCAAGCG GCTGCGGCTT
181  CAGAAGCGAG GCACAGGTGA GCAGGGCAGG TGCTGCGGCT TCCCGTGGCC TTTGGGCAGC
241  CCTGTTTCCT CCGCCCCTGAC TTGCTGTCCC CAGGCGGTGT GGACAAGGCT GCGGTGGGCG
301  GGGTCTTCGA CGTCTCCAAC GCTGACCGCC TGGGCTTCTC AGAGGTGGAG CTGGTGCAGA
361  TGCTGGACGG AGTGAAGCTG CTCATCGAGA TGGAACAGCG GCTGGAGCAG GGCCAGGCCA
421  TCGACGACCT CATGCCTGCC CAGAAATGAA GCCCGGCCCA CACCGACACA GCCCTGCTGC
481  TTCCTAACTT ATTGCCTgGG CAGTGCACCA TGCACCCTGA TGTTCGCCGT CTGACGCCCT
541  TAGCCCTTGCT GTAGAGACTT cCGTCACCTT GGTAGAGTTT ATTTTtGAT
```

Sequence displayed from position 1 to end (position 589)

Sequence numbered from position 1

DUI45 INHIBITION BY HOMOCYCLOCREATINE

FIG. 8

BNSDOCID <WO_____9208456A2_I_>

Cyclocreatine Inhibits the Growth of Multiple Colon
Carcinoma Cell Lines
(7 Day Exposure)

FIG. 9

Effects of 4mg/ml Homocyclocreatine on Various Cell Lines

FIG. 10A

Effects of
4mg/ml l-carboxymethyl-2-iminohexahydropyrimidine
on Various Cell Lines

FIG. IOB

Effects of 4mg/ml Cyclocreatine on Various Cell Lines

FIG. IOC

Effects of 4mg/ml Guanidino Acetic Acid on Various Cell Lines

FIG. IOD

SUBSTITUTE SHEET

Effects of 4mg/ml Creatine Analogs on Cervical Cell Lines

FIG. II

AM285 Inhibits the Growth in Nude Mice of Transplanted Tumor Fragments Derived from the Human Colon Adenocarcinoma Cell Line SW48

FIG. 12

FIG. 13

AM285 Inhibits Growth of Established and Non-Established
Tumors Derived from ME180 Cells in Nude Mice

(54) Title: METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED

(57) Abstract

A method of inhibiting growth, transformation, and/or metastasis of mammalian cells, particularly epithelial cells, in which activity of at least one enzyme, which participates in purine metabolism or regulation of nucleotide levels or the relative ratios of their phosphorylated states, is elevated. In particular, a method of inhibiting transformation, growth and/or metastasis of mammalian cells in which a DNA tumor virus, a DNA tumor virus factor or other factor which has an equivalent effect on cells has acted.

INTERNATIONAL SEARCH REPORT

I. CLASSIFICATION OF SUBJECT MATTER   (if several classification symbols apply, indicate all)°

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl.5   A 61 K 31/415   A 61 K 31/495   A 61 K 31/195
C 12 Q   1/50

II. FIELDS SEARCHED

Minimum Documentation Searched[7]	
Classification System	Classification Symbols
Int.Cl.5	A 61 K

Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched[8]

III. DOCUMENTS CONSIDERED TO BE RELEVANT[9]

Category°	Citation of Document,[11] with indication, where appropriate, of the relevant passages[12]	Relevant to Claim No.[13]
X	WO,A,9009192 (MASSACHUSETTS INSTITUTE OF TECHNOLOGY) 23 August 1990, see the abstract; page 46, line 8 - page 47, line 7; page 49, lines 1-3; claims -----	1-26

° Special categories of cited documents :[10]

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
31-01-1992	2 3. 06. 92

International Searching Authority	Signature of Authorized Officer
EUROPEAN PATENT OFFICE	D. 46au

Mme Dagmar FRANK

FURTHER INFORMATION CO...INUED FROM THE SECOND SHEET

V. ☐ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE [1]

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim numbers   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers   because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers   because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING [2]

This International Searching Authority found multiple inventions in this International application as follows:

FOR FURTHER INFORMATION PLEASE SEE FORM PCT/ISA/206 SENT TO YOU 04-03-1992.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the International application

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the International application for which fees were paid, specifically claims:

3. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

     1-26 (partially)

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.

US 9108275
SA   53568

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 09/06/92
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 9009192	23-08-90	AU-A- 5196990	05-09-90
		EP-A- 0458901	04-12-91

EPO FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)